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Abstract 
 
Early Growth Response Genes (EGR) is a family of four transcription factors containing a 
unique zinc finger domain. EGR-2 and EGR-3 are important for hindbrain development 
and myelination. These transcription factors are also necessary for lymphocyte function 
however, the mechanisms are still unclear. Previous findings have shown that EGR-2cKO 
mice develop lupus-like autoimmune disease with high levels of pro-inflammatory 
cytokines despite showing normal T and B cell proliferation after mitogenic stimulation. 
Therefore we established the CD2-EGR-2-/-EGR-3-/- mouse model to explore the 
phenotype, susceptibility to autoimmune disease and relevant lymphocyte function. We 
discovered that CD2-EGR-2-/-EGR-3-/- mice developed severe systemic autoimmune 
disease and expressed high levels of inflammatory cytokines. More importantly we 
discovered a novel finding that CD2-EGR-2-/-EGR-3-/- T and B cells had impaired cell 
proliferation after mitogenic stimulation.  
 Further investigations revealed that the molecular mechanism defected in the T 
cell receptor signalling pathway is due to a dysfunction in Activator Protein-1 (AP-1).  AP-
1 is a heterodimeric protein composed of AP-1 family members including Jun, Atf and 
Fos. Our data shows that EGR-2 and EGR-3 directly bind with the Atf family member Batf, 
which prevents Batf’s inhibitory function on AP-1 activation. This research demonstrates 
that EGR-2 and EGR-3 intrinsically regulate chronic inflammation and also positively 
regulate antigen receptor activation. In conclusion EGR-2 and EGR-3 are essential for 
providing optimal immune responses, whilst limiting inflammatory immunopathology. 
We propose that this new model could be used for studying autoimmune disease. 
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Chapter 1: Introduction  
 2 
 
 
1.1 Function of the Immune System 
 
 The Immune System is a complex system that involves many different cellular 
processes and molecules to primarily protect the body from the invasion of infectious 
pathogens such as bacteria, viruses, fungi and parasites outside of the body. It is also 
involved in protection from overt proliferation causing cancer and auto reactivity in 
autoimmunity and is divided into two main branches; innate and adaptive immunity. The 
innate immune system is the first to encounter the pathogen and produces a fast and 
rapid immune response. Adaptive immunity in contrast is an immune specific cell 
mediated response (Naik., 2003; Marcos et al., 2003). 
 
1.1.1  Innate and Adaptive Immunity 
 
 Both the Innate and Adaptive immune systems work together for the effective 
clearance of a pathogen. Innate immunity is a non-specific type of response and is the 
first to encounter a pathogen. Innate immune molecules are situated near pathogen 
entry sites making chemical and physical barriers whilst circulating in the blood. These 
types of entry sites include enzymes in sweat, tears and hair movements in bronchial 
epithelium. Innate molecules that circulate in the blood include neutrophils, 
macrophages, complement molecules and monocytes. 
 Some of the pathogens have proteins and cell surface markers called pathogen 
associated molecular patterns (PAMP) that are recognised by macrophages and allow 
them to be identified and ingested. These types of PAMP include lipopolysaccharides 
 3 
 
(LPS) on bacteria, cell wall components on gram negative and positive bacteria, double 
stranded RNA in viruses and flagellin (Marcos et al., 2003). Uptake of the pathogen by 
macrophages can release cytokines to recruit other cells from the immune system and 
provides a link between innate and adaptive immunity (Mackay and Rosen., 2000). 
 Adaptive immunity is an antigen specific immune response by the recognition of 
the pathogen on antigen specific receptors on T and B lymphocytes.  T cells recognise the 
foreign antigen from antigen presentation by professional antigen presenting cells (APC) 
where the pathogen is complexed to the major histocompatibility complex (MHC) 
(Mackay and Rosen., 2000). 
 T cells are further divided into two types, cytotoxic T cells and helper T cells. 
Cytotoxic T cells are defined as CD8+ cells based on this receptor that they bear. Upon 
encountering a pathogen, they release perforins to perforate the cell membrane of the 
pathogen and lytic enzymes and granzymes to lyse and kill.  Helper T cells bear the CD4+ 
receptor and they are responsible for helping to recruit and activate other cells of the 
immune system such as macrophages, B cells and CD8 T cells by releasing cytokines 
(Mackay and Rosen., 2000; Marcos et al., 2003). 
 B cells on the other hand produce a humoral immune response, as they recognise 
the pathogen by the B cell receptor, they release antibodies to neutralise the antigen 
preventing it from adhering to other cells or recruiting other cells like macrophages to 
phagocytise (Mackay and Rosen., 2000; Marcos et al., 2003). 
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1.2 Adaptive Immune Response  
1.2.1 How B and T cells recognise antigens 
 
 The adaptive immune response in contrast to the innate immune response as 
already mentioned, generates an antigen specific immune response to a wide variety of 
different pathogens. For B cells, their antigen receptor contains immunoglobulins (Ig) 
which are specific to a wide variety of pathogens; each B cell has a different membrane 
bound immunoglobulin. Once an interaction is made between the pathogen and B cell, 
the immunoglobulin generates antibodies to eliminate the pathogen and recruit other 
immune cells to the infected area. The antigen receptor of B cells contains a variable 
region and constant region. The variable region is different for each B cell and the 
constant region is important for eliciting B cell effector function. 
 For T cells they contain a T cell receptor that contains variable and constant 
regions, however they do not directly bind to the pathogen, they require the protein to 
be processed and presented with the association of MHC on APC. There are many 
different varieties of MHC across species and populations; MHC class I molecules are 
present on most cells whereas MHC class 2 is restricted to antigen presenting cells and B 
lymphocytes (Surh and Sprent., 2000; Williams and Bevan., 2007; Murphy., 2008; Arens 
and Scoenberger., 2010). 
1.2.1.1 B cell receptor structure  
 
As already described the B cell receptor contains immunoglobulin which is 
secreted as antibodies once activated.  Antibodies are y-shaped molecules that contain 
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two heavy chains and two light chains. The heavy chains link to the light chains with 
disulphide bonds to maintain the structure. The heavy chain distinguishes the classes of 
immunoglobulin. There are 5 different classes of immunoglobulin, IgM, IgD, IgA, IgE and 
IgG, which is the most abundant. The classes of immunoglobulin are distinguished from 
each other by the carboxy terminal in the heavy chain.  
 The light chains vary amongst the immunoglobulins and can contain either the 
lambda (λ) or kappa (κ) chains. The y shaped structure of the antibody is assembled with 
a light chain and the heavy chain, whilst both the variable and constant regions pair up 
separately joining the two light and heavy chains together. The antibody structure also 
contains Fab (fragment antigen binding) and Fc (fragment crystallisable) fragments.  The 
Fab fragment is involved in antigen binding whereas the Fc fragment is important for 
binding to effector molecules (Murphy., 2008). 
Below is a figure showing the immunoglobulin structure (Figure. 1) 
 
Figure 1: Immunoglobulin structure. (Fix, D.F.,1997-2013)  
 
1.2.1.2 T cell receptor structure 
 
 The T cell receptor (TCR) contains T cell receptor α (TCRα) and β (TCRβ) chains. 
These chains intercalate with each other through disulphide bonding and are important 
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for antigen binding. The TCR is very similar to the B cell receptor in that it contains both 
variable and constant regions and held together by disulphide bonds.  Each TCR is 
different on each T cell within the variable region (Murphy., 2008).  
Displayed below is a figure showing the TCR structure (Figure. 2).  More detail about the 
TCR will be described in the TCR signalling section.  
 
Figure 2: T cell receptor structure. (Fix, D.F., 1997-2013) 
 
1.2.2 CD4 and CD8 cell surface markers distinguish T cells  
 
 As already explained, T cells require APC to process the pathogen with the 
associated MHC before T cells can be activated. T cells themselves are classified into two 
major categories with different effector functions. They are differentiated from each 
other by the expression of the cell surface proteins CD4 or CD8 as already described. 
These two different subsets are activated based on which MHC molecule is associated 
with the pathogen. CD4 T cells recognise MHC class II, whereas CD8 T cells recognise MHC 
class I. The CD4 cell surface antigen is composed of four domains, D1/D3, and D2/D4. 
MHC class II binds to the CD4 receptor through the D1 domain. The CD8 co-receptor is 
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different to CD4, in that it does not contain domains, rather it has α and β chains linked 
together by disulphide bonds (Murphy., 2008). 
 
1.2.3 Gene composition in the immunoglobulin and T cell receptor  
  
 The immunoglobulin is composed of the variable (V), joining (J) and diversity (D) 
gene segments which are important for generating the heavy and light chains. 
Rearrangement of the V, J and D segments give rise to varying receptors amongst B and T 
cells. This gene rearrangement is carried out by recombinase enzymes called RAG 
(Recombination activating genes)-1 and RAG-2 and are expressed during lymphocyte 
development in the bone marrow. B cells can further undergo gene rearrangement 
known as somatic hypermutation which allows even more diversity in the B cell receptor. 
The TCR gene rearrangement is similar to immunoglobulins, except T cell development 
occurs in the thymus (Murphy., 2008). 
 
1.2.4 T cell Receptor (TCR) signalling 
  
 T cell responses to self-antigen and foreign antigen, are networked by different 
signalling pathways. It is the ability of the TCR to have a low activation to self MHC whilst 
maintaining homeostasis and a high activation to foreign antigens.  Once TCR and APC 
engagement has occurred, this will set up the TCR signalling pathway which will allow the 
T cell to become activated. 
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 The TCR signalling pathway depends upon responses by chemokines, cytokines, 
transcription factors and other molecules which will manipulate the TCR complex.  
 TCR signalling involves three major stages, CD3 phosphorylation, calcium 
mediated signalling and Ras-mitogen activated protein kinase signalling, which are 
outlined below in figure 4 (Quintana et al., 2005; Morris and Allen., 2012).  
 
 
Figure 3: TCR signalling events. (Morris and Allen., 2012) 
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1.2.4.1 CD3 phosphorylation 
 
 CD3 phosphorylation occurs in the TCR where there is a conformational change in 
the CD3 chains. The TCR contains α and β transmembrane chains that recognises 
antigens. The αβ chains form a heterodimer with one of the homodimers containing ζ-
chains and CD3 (one γ, one δ and three ε-chains). CD3 phosphorylation involves 
conformational changes in CD3ε and CD3ζ chains to expose immunoreceptor tyrosine 
based activation motifs (ITAMs) on the plasma membrane. The γ,δ, ζ and ε chains in the 
TCR make the ITAMs to initiate signal induction into the cell. This initialises Src kinases, 
Fyn and Lck to phosphorylate the tyrosine residues in the ITAM. CD3 phosphorylation 
initialises phosphorylation of other adaptor molecules.  
 Once CD3 is phosphorylated, this recruits the protein tyrosine kinases (PTK) like ζ-
chain associated protein of 70kDa (ZAP-70), p59fyn and p56lck. ZAP-70 is involved in 
phosphorylating the adaptor proteins LAT and SLP76 and subsequently activates Ras 
through guanine-nucleotide exchange factors (GEF) and phospholipase Cγ (PLCγ) by Src-
like tyrosine kinase Tec. Signalling through protein kinase C (PKC) to activate PLCγ 
involves the splicing of phosphatidylinositol 4, 5 bisphosphate (PIP2) which generates 
intermediate molcecules diacyglycerol (DAG) and  Inositol 1, 4, 5 trisphosphate (InsP3). 
InsP3 then binds to its receptor on the endoplasmic reticulum to release stored calcium 
(Ca2+).   
 The mechanism of how CD3 phosphorylation is different in optimal immune 
responses and anergy is still unclear. However it is believed that CD3 phosphorylation to 
foreign antigens is higher whereas TCR signalling to self pMHC involves incomplete CD3 
phosphorylation which generates little or no T cell activation.  The binding strength of the 
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TCR-pMHC complex to develop into T cell activation or not could also be important 
(Rellahan et al., 1997; Quintana et al., 2005; Zehn et al., 2012). 
  
1.2.4.2 Calcium mediated signalling 
 
 Once InsP3 associates with its InsP3 receptor (InsP3R) on the endoplasmic 
reticulum, this allows the channelling of Ca2+ from the stored compartment to the 
cytosol.  The Ca2+ channelling system is activated when there is a low Ca2+ in the plasma 
membrane causing the influx into the cytosol. Low stored levels of Ca2+ initialise calcium 
release activated Ca2+ (CRAC) channels which elevate Ca2+ levels in the plasma 
membrane that in turn activates phosphatase calcineurin. The flow of Ca2+ is modulated 
by the membrane polarity, where depolarisation decreases Ca2+ entry and 
hyperpolarisation increases Ca2+ entry.  Calcineurin then dephosphorylates nuclear 
factor of activated T cells (NFAT) by revealing its nuclear localisation signals and allowing 
its shipment from the cytosol to the nucleus. The influx of Ca2+ can act as a stimulus for 
activating NFAT, nuclear factor-κB (NF- κB), PKC and activator protein-1 (AP-1). NFAT also 
forms complexes with AP-1 for activation.  
 Further downstream of Ca2+ signalling, Extracellular signal-regulated kinases (ERK) 
signalling is important allowing T cells to survive and proliferate whilst initiating a T cell 
response. ERK phosphorylates FOX03 and causes its degradation, which leads to the 
inhibition of Bim and allows T cells to survive. ERK also plays a role in regulating AP-1 
activation. Upstream of ERK, PKC-θ, DAG and RasGRP1 further activate the T cells and 
enhance IL-2 production. (Rellahan et al., 1997; Quintana et al., 2005; Zehn et al., 2012) 
 11 
 
 Recent data has also shown that Ca2+ induction requires the upregulation of EGR-
1 that will increase c-Jun and CREB phosphorylation in glucose stimulated insulinoma cells 
for ERK signalling (Quintana et al., 2005; Muller et al., 2012). 
 
1.2.4.3 Ras-mitogen-activated protein kinase (MAPK) signalling  
 
 Ras then downstream activates the mitogen-activated protein kinase (MAP 
kinase) signalling pathway. The MAPK pathway, involves a signalling cascade with the 
eventual activation of AP-1 and IL-2 production, via phosphorylation of ERK-1, ERK-2 and 
the c-Jun amino-terminal kinases (JNK-1), JNK is for phosphorylating c-Jun at Ser63 and 
Ser73. JNK activation is believed to be initiated by MAPK kinase kinase MEKK1 and 
involves the TCR/CD3 or CD28 pathway. These molecules are phosphorylated by active 
p21Ras (GTP-21Ras) from the GDP form. p21Ras also activates a transcription factor, ELK-
1 that is involved in initiating the transcription of Fos genes, vital for forming 
heterodimers with Jun in AP-1 activation. This mediates the activation of the transcription 
factors NFAT, NF-κB and AP-1 and IL-2 transcription (Huang et al., 2012). Furthermore it is 
the activation of NF-κB and AP-1 signalling that is crucial for full T cell activation 
otherwise, causing anergy. NF-κB and AP-1 are regulated upstream by Protein kinase C θ 
(PKCθ) (Quintana et al., 2005; Schwarz., 2007; Lupino et al., 2012; Morris and Allen., 
2012).  
 NFAT is a transcription factor that contains 3 members, NFAT1, NFAT2 and NFAT4. 
NFAT1 is the main protein in naïve T cells. As already shown, NFAT is activated by the 
influx of Ca2+ into the cytosol and subsequent calcineurin dephosphorylation of NFAT.  
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 NF-κB is a transcription factor composed of dimers that are normally associated 
with the inhibitory molecule, IκB. Once a T cell has been activated, phosphorylation 
occurs and causes the breakdown of IκB and release of NF-κB into the nucleus (Lupino et 
al., 2012). 
 AP-1 is a dimeric complex composed of Jun and Fos families, a more detailed 
description is described in section 1.2.4.5 and it’s activation is mediated by co-stimulation 
in the CD28 pathway.  
 IL-2 production via AP-1/NFAT signalling is essential for T cell activation and 
proliferation to elicit an immune response after TCR activation. AP-1 has two promoter 
sites in the IL-2 gene. Whereas NFAT has five binding sites in the IL-2 promoter and one of 
those allows both AP-1 and NFAT to bind together (Folleta et al., 1998). 
 
1.2.4.4 Pre-TCR signalling    
 
 TCR signalling is also important in thymocyte development. In the early stages of 
thymocyte development, there is no TCRαβ and pMHC influence, in fact, signalling and 
cytokine secretion from IL-7 and Notch1 are sufficient.  Latter stages of thymocyte 
development require TCR rearrangement and expression of CD4 and CD8 coreceptors.  
 The commitment to form fully functional TCRαβ heterodimers from double 
negative (DN) thymocytes is complex. The DN thymocytes CD4-CD8- rearrange TCRβ with 
invariant pre-TCRα chain to form the pre-TCR complex by dimerization. The dimerization 
ensures correct development into the CD4+CD8+ double positive (DP) stage. The pre-TCR 
complex will associate with CD3 and proceed for further signalling.  
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 After the formation of the TCR complex, β-selection follows. β-selection initiation 
is formed by the clustering of pre-TCRα molecules followed by CD3 phosphorylation, Zap-
70, Lat and molecule SLP-76 (sets up TCR signals). DN thymocyte signalling requires low 
TCR interaction compared with the latter stages of thymocyte development to provide 
correct TCR signalling. High TCR-pMHC signalling is eliminated at this stage to ensure 
there are no self-reactive TCR’s. 
 After DN transition, the thymocytes mature into DP thymocytes. This involves 
appropriate TCRα rearrangement that can bind with TCRβ to be able to recognise self 
MHC.  Selection of TCR’s that are able to recognise self-MHC molecules are allowed to 
survive. 
  At the DP stage, TCR’s that have a functional TCRα and TCRβ chains will be 
selected by positive selection for their affinity to interact with self-MHC. In this instance, 
TCR’s with the correct orientation will be selected for its ability to recognise self-MHC on 
cortical thymic epithelial cells. TCR’s that do not recognise self-MHC are eliminated.  
 Negative selection then eradicates TCR’s that bind strongly to self-MHC, so that 
TCR’s with low affinity for self-MHC can differentiate into CD4 or CD8 single positive (SP) 
T cells. It is believed that negative selection is caused by increased recruitment of Zap70 
and Lat to the TCR complex, with high ERK signalling (Schwarz., 2007; Kreslavasky et al., 
2010; Blanco et al., 2012; Huang et al., 2012; Morris and Allen., 2012; Zehn et al., 2012). 
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1.2.4.5 AP-1 signalling 
 1.2.4.5.1 AP-1 family and function  
 
 AP-1 is a transcription factor that comprises over twenty proteins from dimeric 
complexes of Fos (c-Fos, FosB, Fra-1, Fra-2 and smaller FosB splice variants FosB2 and 
Deltas FosB2), Jun (c-Jun, JunB, JunD), ATF (activating transcription factor) (Atf2, 
Atf3/Lrf1, Batf, Jdp1 and Jdp2) and Maf (musculoaponeurotic fibrosarcoma) (c-Maf, 
MafB, MafA, MafG/F/K and Nrl) proteins. AP-1 was first discovered as a transcription 
factor involved in the association with the cis-element of the human metallothioneiniIIa 
promoter. Dimerisation in this family involves heterodimeric and homodimeric 
associations between proteins and other genes making AP-1 to have many functions 
including, metastasis, proliferation, survival, angiogenesis, apoptosis and invasion (Zhou 
et al., 2005; Karamouzis et al., 2007; Meng and Xia., 2011).  
 Fos and Jun are the main members of the AP-1 family. They were first discovered 
as viral oncoproteins, v-Fos and v-Jun from an avian sarcoma virus and Finkel-Biskis-
Jinkins osteosarcoma in 1987. They were discovered to be involved in cell transformation 
as their over-expression gave a positive effect (Ivorra et al., 2005; Karamouzis et al., 2007; 
Shaulian., 2010). 
 The AP-1 family of proteins contain the basic leucine-zipper domain (bZIP), basic 
domain and some members have a transactivation domain.  Figure 4 shows the domain 
structures of Jun; Fos and Batf family members. The bZIP is involved in dimerisation with 
other protein members. Where the bZIP contains a leucine zipper motif which is involved 
in creating the dimer associations; however, it also contains a DNA binding domain that 
can interact with DNA consensus sequences in target genes. The bZIP domain consists of 
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α-helices, where every seventh amino acid is a leucine. Once they have bound to DNA 
they can go and activate or repress target genes. Fos and Jun recognise the 12-O-tetra 
decanoylphorbal-13-acetate response (TPA) element found in promoter regions of target 
genes. Other elements they recognise include cAMP-Response Element (CRE), the MAF 
recognition elements (MARES) and the antioxidant response elements (ARES). Normally, 
Jun-Fos heterodimers bind to the TPA sequence (5’-TGA (C/G) TCA-3’) and Jun-Atf binds 
to CRE (5’-TGACGTCA-3’) (Ivorra et al., 2005; Karamouzis et al., 2007; Shaulian., 2010). 
 
 
Figure 4: Domain Structures of Jun, Fos and Batf. (Murphy et al., 2013) 
 
 As already described the homo and heterodimers are important for AP-1 function 
and the combinations between AP-1 family members is important for stabilisation and 
transcription of other genes. Jun family members can form homo or heterodimers with 
Fos or Atf members. Jun and Fos heterodimers are more stable than Jun/Jun 
homodimers. Figure 5 shows the Fos and Jun heterodimer formation that bind to AP-1 
sites in promoter regions of genes. c-Maf and Nrl can form heterodimers with c-Fos or c-
Jun but MafB/G/F/K form dimers with only Fos not Jun. For example c-Jun-Atf2 binding 
triggers growth factor independence, whilst c-Jun-c-Fos binding activates anchorage 
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independent growth. These different dimer forms can be important for tumorgenesis. 
Also, Fra-2 and JunD heterodimers are important for CCR4 and cell proliferation in Adult T 
cell leukemia. Fra-1 and JunD or Fra-2 and JunB or Fra-2 and JunD heterodimers bind to 
proto-oncognenes like c-Myb and BCL-6 which are important proliferation. Typically, AP-1 
can bind with other elements or genes, not just AP-1 members that contain core 
transcriptional sequences like TATA box in target genes. AP-1 binding to target genes is 
also influenced by growth factors, cytokines and oncoproteins that can have profound 
effects on proliferation, survival, differentiation, transformation, apoptosis and TCR 
signalling (Foletta et al., 1998; Karamouzis et al., 2007; Nakayama et al., 2008; Shaulian., 
2010).  
 
Figure 5: Jun and Fos heterodimer binding which initiates AP-1 activation and binds to 
AP-1 binding sites in target gene promoter sites. (Murphy et al., 2013) 
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1.2.4.5.2 Regulation of AP-1 activity 
 
 Protein kinases are important for the transmission of extracellular signals through 
the cytoplasm and phosphorylating other transcription factors including AP-1 family 
members Jun. Both JNK and ERK are members of MAPK. They are activated through 
phosphorylation on tyrosine and threonine residues in the motif. Phosphorylation is 
achieved by MAP kinase kinases (MAPKKs). The MAPKKs MEK4 and MEK7 activate the 
JNKS; whilst, MEK1 and MEK2 activate ERK and MEK3 and MEK6 activate p38. MAPKKs 
are further phosphorylated by MAPKK kinases (MAPKKK).  
 The MAPKKK family is made up of more than 20 protein kinases including Rafs, 
MEK kinases, germinal centre kinases (GCK), mixed lineage kinases (MLK), apoptosis-
stimulated kinase 1 (ASK-1) and TGF-beta activated adaptors (TAK) (Karamouzis et al., 
2007; Higai et al., 2009; Shaulian., 2010).  
 Once MAPK activates JNK, JNK gets translocated into the nucleus and 
phosphorylates Jun. JNK can also phosphorylate and activate JunD and Atf-2. JNK 
expression is affected by hormones, cytokines, growth factors, deregulated oncogene 
expression and cellular stresses including UV.  
 There are three different genes in JNK; JNK1, JNK2 and JNK3. JNK1 and JNK2 are 
ubiquitously expressed in cells, whilst JNK3 is expressed only in the brain. JNK 
phosphorylates c-Jun at serine 63 and 73 and threonine 91 or 93 for activation and 
prevents ubiquitin dependent degradation of c-Jun. The ability of JNK to phosphorylate 
JunB has been controversial; however, it is believed to be phosphorylated at threonine 
102 and 104. Commonly JNK binding to Jun proteins enhances their ability to engage in 
gene transcription. Data has shown that JNK1 deficiency does reduce expression of c-Jun 
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and cyclin D, thus reducing cell proliferation (Karin., 1995; Ukarami et al., 1997; Jochum 
et al., 2001; Eferl and Wagner., 2003; Karamouzis et al., 2007; Shaulian., 2010). 
  
1.2.4.5.3 Atf-like (B-atf) function 
 
 Batf is a component of the AP-1 family of bZIP transcription factors that forms 
heterodimers to Jun proteins and inhibits AP-1 transactivation, as shown in figure 6. Batf 
contains three family members Batf, Batf2 and Batf3. Batf and Batf3 contain two 
domains, the leucine zipper and DNA binding domain; whereas Batf2 also contains an 
unknown function carboxy-terminal domain. The Batf gene is found on human 
chromosome 14q.  Batf is expressed in Th1, Th2, Th17 and TFH T cells. Batf3 is expressed 
in Th1 T cells and nominal in Th17 and Th2 T cells (Murphy et al., 2013).  Batf can form 
dimers with Jun which are less transcriptionally active (Logan et al., 2012). This is 
supported by data showing over expression of Batf blocks AP-1 associated signalling and 
reducing cell growth. Phosphorylation of Batf occurs at serine 43 by DBD (DNA binding 
domain) which oxidises the serine residues and inhibits AP-1 mediated gene expression 
and DNA binding. DBD is also found in other bZIP family members like c-Jun and c-Fos 
(Deppmann et al., 2003). 
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Figure 6: Batf heterodimers with Jun, inhibit AP-1 signalling and prevent binding to AP-1 
binding sites in target gene promoter sequences. (Murphy et al., 2013) 
 
 Batf was suggested to produce inactive transcriptional activity when it is part of a 
complex as forced expression of Batf slows down the growth and transformation of 
fibroblast cells (Echlin et al., 2000).   
 This was confirmed by Echlin et al., 2000 group who isolated portions of the Batf 
protein and fused with the DNA binding domain of the yeast GAL4 promoter. The fusion 
protein was transfected into C3H10T1/2 cells along with the chloramphenicol actyl 
transferase (CAT) reporter plasmid. Measurement of the CAT reporter gene showed that 
none of the Batf fusion proteins were transcriptionally active. However, Batf is also 
important for thymocyte maturation. Batf mRNA expression in thymocytes from WT mice 
is detected in DN and SP thymocytes,  however, Batf expression is not detected in DP 
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thymocytes. These results indicate the differential expression of Batf as thymocytes gain 
the CD4 and CD8 T cell markers, they lose Batf expression, however, maturation into 
single positive thymocytes requires Batf expression (Williams et al., 2001). Transgenic 
mouse cell lines that over-express Batf in thymocytes or splenocytes were crossed with 
C57BL/6 mice that carry the AP-1 luciferase reporter gene to define how Batf regulated 
AP-1 activity. Protein extracts from these mice and AP-1 only reporter gene cells were 
stimulated with concanavalin A and AP-1 luciferase activity was measured. The data 
showed repression in AP-1 trans-activation from AP-1/Batf luciferase thymocytes. This 
was the first report to show that Batf inhibits AP-1 activation following stimulation in T 
cells and was further supported from the AP-1 luciferase reporter assay from cultured 
mouse fibroblast cells (Williams et al., 2001).   
 However, further research has identified Batf to be important for gene 
expression. Batf has shown to be essential for thymic NKT cell development and is 
expressed by both T and B cells. Evidence has shown that Batf transgenic T cells have less 
caspase-3 (apoptotic marker) compared with WT to show that Batf is involved in 
regulating apoptotic signalling. Data has found that over expression of Batf in mice leads 
to the development of lymphoid tumours and this is not due to hyperproliferation, this is 
due to an inadequacy in apoptosis.  However, Batf can also be a positive regulator of 
gene expression. This has been shown by in-vivo results indicating that Batf knockout 
mice show a defect in CD4 Th17 and TFH helper cells. Batf deficient mice have also been 
shown to be resistant to the induction of EAE disease (Logan et al., 2012).  
 Batf has been further shown to be important for Th17 differentiation. Batf 
knockout mice have a normal thymus, spleen and lymph nodes; they have normal Th1 
and Th2 differentiation, whilst Th17 was impaired as ROR-γt is low, thus IL-17 cytokine 
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production was also reduced. The Th17 cytokines include IL-17A, IL-17F, IL-21, IL-22 and 
IL-26 (Schramal et al., 2009; Montelione et al., 2011). In contrast Batf transgenic mice had 
increased expression of Th17 cytokines. In this study Batf transgenic mice developed EAE 
disease, whereas Batf knockout mice were resistant, displayed by low IL-17. Batf directly 
binds to the IL-17 promoter. Batf controls Th17 differentiation by regulating IL-6, TGF-β 
and subsequently STAT3 (Schraml et al., 2009).  
 Batf is expressed after T cell activation and is shown to be involved in T cell 
differentiation at the point of signal three which requires IL-12 for full T cell activation. 
Batf and c-Jun inhibit Sirt1 (histone deacetylase that promotes gene silencing). By 
inhibiting this enzyme, there will be an increase in histone acetylation of other target 
genes including T-bet, a gene involved in effector cell differentiation, which increases 
NAD+ for glycolysis, TCA and oxidative phosphorylation resulting in production of ATP 
levels to initiate T cell differentiation and survival (Kuroda et al., 2011; Liao et al., 2011). 
  
1.2.5 T cell mediated immune activation  
 
 As already described the adaptive immune response generates a specific response 
orchestrated by T and B cells. Predominantly the immune response is classified into three 
major phases. The first phase is termed the effector phase where naïve T cells are primed 
with antigen on the APC cells. In the effector phase, T cell activation requires three 
signals before differentiation and expansion. Naïve T cells will differentiate into either 
CD8 cytotoxic T cells or the CD4 helper T cells that contain further subtypes Th1, Th2 or 
Th17. The second phase is termed the contraction phase where the effector T cells carry 
out their effector function for pathogen clearance and up to 90% of those cells once their 
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effector function has been carried out, will undergo programmed cell death. The final 
phase is called the memory phase where the remaining 5-10% of the effector T cells will 
become long lived memory T cells that will circulate in the periphery. Lymphocyte 
numbers in the secondary peripheral lymphoid numbers are maintained at constant 
numbers prior to an infection and when the infection is cleared. This process is regulated 
by cytokines. When there is no invasion of any pathogen, there will be 1 in 100,000 naïve 
T cells that will be specific to a pathogen. However, once there is an invasion of a foreign 
pathogen, the antigen specific T cells for those will be activated and expand typically for 
fourteen days in humans to 50,000 cells (Boymen et al., 2007; Williams and Bevan., 2007; 
Zehn et al., 2012).   
 
1.2.5.1 Naïve T cell presentation of antigen by antigen presenting cells  
 
 A sustained interaction between the T cell and APC is important for initiating 
sufficient T cell activation. APC’s are a subset of cells that are involved in innate immunity 
because they do not specifically bind to any particular pathogen, however they have 
receptors that recognise common pathogen cell surface molecules such as LPS, 
peptidoglycan, dsRNA, ssRNA etc. There are three professional APC’s in the immune 
system; these are macrophages, dendritic cells and B cells. Macrophages and dendritic 
cells are able to recognise foreign pathogens such as bacteria, fungi and viruses through 
interactions with their cell surface receptors like, Toll-like receptor, DC-SIGN, mannose 
receptor, scavenger receptor etc. Once a pathogen enters the body and the common 
pathogen cell surface markers are recognised, the pathogen is then processed to become 
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peptides and associated with MHC for naïve T cell activation. For B cells, they can directly 
elicit a humoral response.  
 Constantly APC’s not only present foreign antigens, they also present self-antigens 
to T cells; this evokes the tolerance mechanism, where there is no activation of the 
immune response to self (Surh and Sprent., 2000; Williams and Bevan., 2007; Murphy., 
2008; Arens and Scoenberger., 2010).  
 Naive T cell activation requires the pathogen to be loaded and processed into a 
peptide associated with MHC on APC’s.  In the absence of MHC, naïve T cell numbers will 
deplete. Depending on which MHC molecule the antigen presenting cell has, this will 
activate the appropriate T cell. Dendritic cells have the unique ability to evoke a much 
stronger T cell immune response when stimulated with inflammatory cytokines like IFN 
that will drive the differentiation of resting dendritic cells into an activated state. Only in 
the activated state the dendritic cell will mediate a T cell response. The dendritic cells 
also express cytokines and chemokines to drive the T cell immune response.  These 
PAMPS will induce activation of the APC to present to T cells by releasing cytokines, 
costimulatory molecules and migration into secondary lymphoid organs (Surh and 
Sprent., 2000; Williams and Bevan., 2007; Arens and Scoenberger., 2010).  
 
1.2.5.2 Naïve T cell activation and expansion by antigen presentation priming 
 
 There is a wide diversity of the TCR to be able to interact with a variety of 
different pathogens. T cell activation through appropriate TCR-peptide-MHC complex 
requires activation signals. Without these signals, T cells cannot be appropriately 
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activated and will become unresponsive. Figure 7 outlines all the required T cell signals 
for activation.  
  Signal 1 is generated by the engagement of the TCR on the T cell and the peptide-
MHC complex on the APC.  This then causes the conformational change known as CD3 
phosphorylation as already described to initiate T cell activation. Engagement of signal 1 
alone induces anergy (Surh and Sprent., 2000; Williams and Bevan., 2007; Arens and 
Scoenberger., 2010).  
 The second signal is generated through the expression of costimulatory molecules 
on the APC. The costimulatory receptors on the T cell drive T cell activation, whereas 
insufficient costimulation will evoke the T cell into anergy. One of the main costimulatory 
receptors on T cells is the immunoglobulin member CD28. CD28 is expressed on all naïve 
T cells.  CD28 will interact with the B7 receptor on the APC. Other common interactions 
are between DC-SIGN (on APC) and ICAM-1 (T cell) or between CD40 (APC) and CD40L (T 
cell). There are also other co-receptors like CTLA-4, PD-1, ICOS and 4-1BB which can 
evoke immunosuppressive signals.  The interactions in signal 2 evoke survival and 
differentiation into effector cells by upregulation of IL-2, IL-7 and the down regulation of 
TGF-β (Oehen and Brduscha-Riem., 1998; Surh and Sprent., 2000; Williams and Bevan., 
2007; Blache et al., 2009; Arens and Scoenberger., 2010).                                                                                                                                                                                            
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Figure 7: Antigen Presenting cell and CD8 T cell activation. (Arens and Scoenberger., 
2010) 
 
 A third signal has also been identified to be important along with signal 1 and 2. 
The third signal is generated through the up regulation of cytokines involved in expansion 
and effector functions seen in T cells, these cytokines include IL-12, IFN-γ and Type 1 IFN 
produced by APC’s. Research has shown that in the absence of IL-12, CD8 T cells have an 
impaired ability to differentiate into effector T cells. When CD8 T cells were 
supplemented with IL-12, they produced a better protection against an infection outlining 
the importance of generating the third signal for an immune response (Oehen and 
Brduscha-Riem., 1998; Surh and Sprent., 2005; Williams and Bevan., 2007; Arens and 
Scoenberger., 2010).  
 
1.2.5.3 Role of cytokines in T cell activation and expansion  
 
 When all three activation signals have been generated, the naïve T cells will 
undergo massive expansion and proliferation into the contraction phase resulting in an 
infiltration of effector T cells to carry out their function (Surh and Sprent., 2005). To 
enable naïve T cell numbers to undergo expansion, certain cytokines and genes are up-
regulated for the survival and homeostatic pathways. The main players involved include, 
IL-2, IL-4, IL-7, IL-18, IL-19, IL-15, IL-21 and IFN-γ (Oehen and Brduscha-Riem., 1998; Tan et 
al., 2001; Karman et al., 2004; Badovinac et al., 2005; Ishimaru et al., 2006; Snyder et al., 
2008; Sener et al., 2009; Keller et al., 2010).  
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  IL-2 is the major cytokine involved in the activation and proliferation of T cells. IL-
4, IL-7, IL-15 and IL-21 are pivotal for the survival of these effector T cells (Schluns and 
Lefrancois., 2003; Ishimaru et al., 2006).  
 The cytokine suppressor of cytokine signalling-1 (SOCS-1) has been shown to be 
essential for regulating the activation of naïve T cells to self-antigens with IL-15. It has 
been reported that SOCS-1 deficient naïve CD8 T cells that were adoptively transferred 
into normal mice showed high T cell pool numbers when there is no IL-15 (Boymen et al., 
2007).  
 There are also cytokines that are involved in suppressing the immune system. 
Transforming growth factor-β (TGF-β) has been shown to be important for suppressing 
the immune system. Also IL-10 has been shown to have suppressive properties by 
reducing the expression of cytokines IL-2 and IFN-γ (Boymen et al., 2007; Sprent et al., 
2008; Cardone et al., 2010).  
 Transcription factors are important in carrying out an immune response, 
including, NFAT and NF-κB (Oehen and Brduscha-Riem., 1998; Surh and Sprent., 2000; 
Ganusov et al., 2007; Blache et al., 2009; Sener et al., 2009). 
 
1.2.5.4 Naïve T cell markers  
 
 Naïve T cells and all the other T cell subsets, like effector or memory, have 
phenotypic cell surface markers that are expressed to make them distinct from other cell 
types. For naive CD8 T cells they bear IL-7+, TGF-β-, CD122int, IL-7Rαhi, CD5hi, CD195hi, 
CD197hi, CD134hi, CD152hi and CD25hi . For naive CD4 T cells they have IL-7+, TGF-β-, 
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CD122lo/int, IL-7Rαhi, CD5hi, CD195hi, CD197hi, CD134hi, CD152hi and CD25hi  (Boymen et al., 
2007; Williams and Bevan., 2007; Wells., 2009; Zhang et al., 2009). 
 
1.2.5.5 T cells differentiate into subclasses of effector T cells 
1.2.5.5.1 CD4 effector T cells 
1.2.5.5.1.1 CD4 effector T cell subclasses 
 
 Helper T cells are further differentiated into distinct subtypes capable of carrying 
out different helper T cell functions. Activation of transcription factors and differential 
cytokine expression will give rise to a different CD4 subtype as shown in Figure 8.  
 The Th1 helper T cells are type 1 effector cells which mediate expression of IFN-γ 
and IL-2 to help clear the pathogen through helping the activation of CD8 T cells and 
macrophages. CD4 T cells have been shown to secrete signals that are vital for CD8 
activation independently or dependently. It has been shown that sustained and effective 
CD8 T cell response requires CD4 help to be able to maintain efficient IFN-γ production. 
 The Th1 subtype is mediated through IL-12, Type 1 IFN, IL-1β, IL-21, TNF-α 
secretion and the transcription factor T-bet expression to enable an effector function. 
Th1 T cell development is governed by STAT1 activation induced by the expression of IFN-
γ and IL-27 cytokine production by APCs and NK cells. In turn this induces the master 
regulator of Th1 differentiation, the transcription factor T-bet which allows the 
expression of the signature cytokine IFN-γ (Haynes et al., 2003; Anderson et al., 2006; 
Williams and Bevan., 2007; Okamura et al., 2009; Sallusto and Lanzavecchia., 2009; 
Putheti et al., 2010). 
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 Another CD4 helper T cell subtype is Th2. These cells are involved in activating B 
cells to release antibodies and protection against helminth infections. They require the 
transcription factor GATA-3 and c-Maf to be able to carry out the effector function and to 
mediate the expression of cytokines, IL-4, IL-5, IL-13 and TGF-β. Th2 development 
requires STAT6 and leads to the induction of the transcription factor GATA-3 and MAF for 
Th2 differentiation. The activation of these transcription factors induces the expression of 
the signature cytokine of Th2, IL-4 (Haynes et al., 2003; Anderson et al., 2006; Wang et 
al., 2006; Williams and Bevan., 2007; Okamura et al., 2009; Sallusto and Lanzavecchia., 
2009; Putheti et al., 2010).  
 Another CD4 helper T cell subtype is Th17, which are involved in initiating an 
inflammatory response. Th17 T cells are also involved in protecting against bacteria and 
fungi and circulate in mucosal tissues. Th17 effector function is carried out by the 
expression of the transcription factor Retinoic-acid-receptor-related orphan receptor- γt  
(RORγt) and the release of the cytokines, IL-17A, IL-17F, IL-22, IL-6, TGF-β, IL-1β, IL-23, IL-
12 and IL-21. Th17 cells also require STAT3 for this lineage type, as STAT3 suppresses IL-
10 inhibitory function. Th17 differentiation has been shown to be driven by TGF-β and IL-
6 secretion. Th17 T cells have been implicated in the development of various 
autoimmune diseases including psoriasis, arthritis and multiple sclerosis (Rangachari and 
Kuchroo., 2013). 
  Mostly over reactivity of Th2 T cells causes allergic immune responses, whereas 
abnormal Th1 and Th17 responses causes autoimmune diseases (Haynes et al., 2003; 
Anderson et al., 2006; Wang et al., 2006; Sallusto and Lanzavecchia., 2009; Wilson et al., 
2009; Putheti et al., 2010; Zhu et al., 2010).  
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 The final main CD4 helper T cell subset is the T regulatory cells (Treg). They 
express CD4+ CD25+ on their cell surface.  These T cells play an important role in causing 
anergy when there is insufficient co-stimulation for T cell activation. They are able to 
cause anergy through up regulation of E3 ligase, cbl-b, GRAIL, Itch and Nedd4. Treg T cells 
are characterised by the expression of the Forkhead transcription factor (FoxP3) and are 
essential for preventing autoimmune disease and maintaining homeostasis. FoxP3 
deficiency in mice causes lymphoproliferation and autoimmune disease (Walzer et al., 
2002; Fontenot et al., 2003; Kmieciak et al., 2009; Putheti et al., 2010).  
 It is believed that there are two types of Treg T cells, one that causes anergy and 
the other controls tissue inflammation. One is believed to circulate in the thymus and the 
other in the periphery. The anergenic Treg is characterised by cell surface expression 
CD4+, CD25+ and FoxP3+. The Treg that controls tissue inflammation is thought to secrete 
IL-10, FoxP3-and CD4+ (Okamura et al., 2009; Sallusto and Lanzavecchia., 2009; Cooles et 
al., 2013). 
 The above four Helper T cell effector T cells are the most established subtypes. 
However, it is now emerging that there could be even more subtypes all with different 
functions. There is believed to be a Th3 subtype that is thought to be involved in inducing 
IgA antibodies and suppress autoimmune diseases, like encephalomyelitis (Anderson et 
al., 2006). There is also the Follicular helper T cells (TFH) subtype that is involved in 
helping B cells. They express the chemokine receptor CXCR5 that stimulates ICOS-1 
expression. TFH T cells are able to produce IL-21 and expresses ICOS, PD-1 and CXCR5, 
which are thought to be the homing receptor for residence in the B cell follicle. TFH cells 
aid the expansion of germinal centres (Sallusto and Lanzavecchia., 2009; Pepper and 
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Jenkins., 2011). TFH T cells are also important for class switching in the germinal centre 
(Zhu et al., 2010). 
                  
Figure 8: Differentiation of CD4 T cells into subtypes. (Pepper and Jenkins., 2011) 
 
1.2.5.5.2 CD8 effector T cells  
 
 CD8 T cells are predominately termed cytotoxic T cells due to the fact they target 
infected cells. CD8 T cells are vital for the protection against viral and bacterial infections. 
These cytolytic T cells express a different set of phenotypic markers compared to other 
lineages, including, IL-12+, IL-2+, IFN-1+, IFN-γ+, T-bet+, BCL-3↑, CD122int, IL-7Rαlo, IL-7+ 
and IL-15+ (Boymen et al., 2007; Williams and Bevan., 2007). 
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1.2.5.5.2.1 Cytotoxic T cells direct killing of pathogen to trigger apoptosis 
 
 The CD8 effector T cells main function is to directly kill the pathogen by 
exocytosis. CD8 T cells release perforin and promote the release of lytic enzymes and 
molecules, like granzymes, perforin and cathepsin to adhere to target cells.  This triggers 
programmed cell death of the pathogen by exocytosis when perforin lysis the pathogen 
cell membrane. This allows the entry of granzymes into the cytoplasm of the pathogen 
and ligation to the Fas death receptor triggering apoptosis. 
 IFN-γ is one of the key cytokines that are produced by CD8 T cells into driving 
cytolytic activity. They also produce IL-2, IL-4, IL-7, IL-15 and IL-21 needed for survival and 
proliferation. IL-2 is needed for T cell proliferation, survival and effective IFN-γ 
expression. IL-4, IL-7 and IL-15 play the role in cell survival of the effector T cells to enable 
them to carry out their functions (Schluns and Lefrancois., 2003; Liu et al., 2004; 
Badovinac et al., 2005; Boymen et al., 2007; Williams and Bevan., 2007). 
 For cytotoxic T cell activation, a number of transcription factors and genes 
including, STAT4, RBP-J, CREB-1, T-bet, Eomes and cKrox are required for the release of 
toxic molecules like granzymes, to kill the pathogen after endocytosis (Kaech et al., 2002; 
Haynes et al., 2003; Williams and Bevan., 2007). 
 
1.2.5.5.2.2 CD8 effector T cell function requires CD4 helper T cells  
 
 To mediate cytotoxic T cell activation, CD8 T cells need CD4 T cell help for effector 
function. The effector CD4 T cell subset, Th1 CD4+ T cells are involved in priming CD8 T 
 32 
 
cell activation by secreting IFN-γ and IL-12 production which further enhance CD8 T cells  
cytotoxic function (Williams and Bevan., 2007). 
 
1.2.5.5.3 Memory T cells and homeostasis 
 
 Memory T cells represent 5-10% of the T cell population and have a TCR that is 
specific to a particular foreign antigen that has been encountered in a previous infection. 
The difference between naïve T cells and memory T cells is that memory T cells can 
mount an immune response when there are lower levels of antigen. They will be able to 
mount a much faster response in a second encounter with the same antigen.   
 The mechanisms of the generation of memory T cells and how they are 
maintained is largely unknown. Their ability to undergo proliferation when naïve T cells 
are adoptively transferred into irradiated or immunodeficient mice shows that memory T 
cell numbers are maintained in a process of homeostatic proliferation. Some of the 
homeostatic proliferation mechanisms involve competition in basal levels of IL-7. It is 
believed that when there are low levels of IL-7 this triggers homeostatic proliferation. T 
cells compete for IL-7 for survival and the consumption of IL-7 would be higher under 
normal conditions. In turn this increases the expression of JAK1, STAT5, BCL-2 and Akt, all 
involved in maintaining cell survival. However, when there are low T cell numbers, there 
would be low IL-7 consumption and this would trigger signalling pathways involved in 
homeostasis including expression of Eomes and triggering the Wnt pathway (Kaech et al., 
2002; Tanchot et al., 2002; Schluns and Lefrancois., 2003; Liu et al., 2004; Jameson., 
2005; Surh and Sprent., 2005; Williams and Bevan., 2007; Surh and Sprent., 2008; Sener 
et al., 2009). 
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 Memory T cells have a distinct set of phenotypic markers that differentiate them 
from other cell lineages: CD44hi, Ly6Chi, CD122hi, CD62Lhi, CD127hi, L-selectinlo and 
CD44RBlo (Boursalian and Bottomly., 1999; Goldrath et al., 2000; Kaech et al., 2002; 
Badovinac et al., 2005). 
 Memory T cells are divided into two different subsets, central or effector memory 
T cells. They have different cell surface homing receptors and cytolytic function.  Central 
memory T cells have the lymphoid homing receptor CCR7+, CD45RA- and CD62Lhi. The 
central memory T cells are found in the secondary lymphoid organs and they have a high 
proliferative capacity but a low effector function. It is believed that the central memory T 
cells are the first to encounter an antigen, proliferate and then differentiate into effector 
memory T cells to carry out their cytolytic functions. Central memory T cells have the 
phenotypic markers, CD44int, CD62hi, CD122-, CCR7+ and CD127+ (Walzer et al., 2002; 
Badovinac et al., 2005; Williams and Bevan., 2007; Surh and Sprent., 2008). 
 Effector memory T cells on the other hand, stay in non-lymphoid organs and they 
possess the ability to have cytolytic function through up regulating the expression of IFN-
γ, however, they have a low proliferative potential. They are involved in carrying out the 
removal of the pathogen and are fully differentiated from central memory T cells. They 
have the phenotypic markers, CD44hi, CD62low, CD122+, CCR7-, CD45RA- and CD127- 
(Kaech et al., 2002; Schluns and Lefrancois., 2003; Badovinac et al., 2005; Surh and 
Sprent., 2005; Williams and Bevan., 2007; Surh and Sprent., 2008).  
 Effector memory T cells will be involved in the initial drive to clearing the 
pathogen whilst the central memory T cells may be involved in the latter stages to boost 
the immune response (Walzer et al., 2002).  
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  A number of cytokines are produced by effector and naïve T cells to sustain 
memory T cell numbers. These cytokines include IL-7, IL-15, IL-12, IL-18, IL-21, INF-α/β 
and IL-2. IL-7 is an important cytokine that is needed for survival and is expressed by 
naïve and effector T cells. IL-15 and IL-21 also share the same function as IL-7 and these 
cytokines promote the expression of other transcription factors involved in sustaining 
survival (Curtsinger et al., 1998; Boursalian and Bottomly., 1999; Walzer et al., 2002; 
Williams and Bevan., 2007; Boymen et al., 2007; Surh and Sprent., 2008). 
 In terms for long term survival of both CD4 and CD8 memory T cells, it is believed 
that mechanisms are independent for both subsets. CD8 memory T cells survive through 
signalling by IL-15 through regulation of CD122 (IL-2/IL-5Rβ) expression dependent on T-
bet and eomesoderm. CD4 memory T cells however, are believed to deplete over time 
because their survival is not dependent on IL-15 signalling. This could be significant for 
understanding memory T cell survival and proliferation in both CD4 and CD8 subsets 
(Kaech et al., 2002; Boymen et al., 2007). 
 
1.3 Failure in host immune defence 
1.3.1 Autoimmune disease 
 
 Autoimmune disease is caused by a breakdown in the immune system or loss of 
tolerance (inactive to self) where the immune system generates immune cells against 
self-cells and tissues which can illicit autoantibodies and inflammation. Autoimmunity is a 
major cause of mortality across the world and currently there is no cure for the disease. 
Exploring the genetic mutations and polymorphisms in DNA that leads to the 
development of autoimmune disease is being studied to identify key therapeutic 
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strategies. Whilst genomic and proteomic studies are being used to identify genes and 
mechanisms involved, autoimmunity is believed to arise from genetic, environmental and 
regulatory defects. Predispose to other infections can also influence the development of 
autoimmune disease (Fatham et al., 2005; Rioux and Abbas., 2005; Murphy., 2008).  
 
1.3.1.1 Self-tolerance and Autoimmunity 
 
 A breakdown in self-tolerance is believed to be essential in the development of 
autoimmunity. Self-tolerance is a mechanism for which the immune cells recognise self-
antigens and do not amount an immune response. Self-tolerance is an important 
checkpoint carried out during the development of B and T cells where those cells that are 
autoreactive to self-antigen will be eliminated. Self-tolerance is further divided into two 
stages, central and periphery (Rioux and Abbas., 2005).  
 
1.3.1.2 Discriminating self and non-self 
 
 The ability of the immune system to distinguish between self and non-self is 
essential for balance in the immune system. A defect in this can cause severe tissue 
damage and autoimmune disease. There are several checkpoints during lymphocyte 
development (central tolerance) and in the periphery (peripheral tolerance). Another 
mechanism of how self and non-self are discriminated is by the levels of antigenic 
presentation. Self-antigens are expressed on every cell and every tissue, so therefore 
presentation of these antigens will be low and constant to lymphocytes. Therefore the 
lymphocytes in this case will become tolerant (inactive) once ligated to the antigen 
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receptor on the lymphocytes. On the other hand, foreign antigens are not commonly on 
cells in the body and when they enter the host, they rapidly divide and release high levels 
of antigen, which is a signal to lymphocytes to generate an immune response (Murphy., 
2008). 
 
1.3.1.3 Central tolerance 
 
 Central tolerance occurs in the lymphoid organs, T cells are in the thymus whilst B 
cells are in the bone marrow. The process of central tolerance involves these immature 
lymphocytes to be presented with self-antigens, if those immature lymphocytes mount 
an immune response, they will undergo apoptosis or inactivation (Rioux and Abbas., 
2005).  
 
1.3.1.4 Peripheral tolerance 
  
 Peripheral tolerance is where mature lymphocytes that have exited from the 
lymphoid organs into tissues are still presented with self-antigens on APC’s and if they 
amount an immune response they are either killed or silenced. Peripheral tolerance 
mechanisms are characterised into three main types, anergy, deletion and suppression 
(Rioux and Abbas., 2005). 
 T cell anergy is defined as causing the silencing or unresponsiveness of the T cell 
when they encounter self-antigens. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a 
receptor that is present on T cells which has an inhibitory function when ligated to the 
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costimulatory molecules CD80 and CD86 on APC’s, thus causing the T cell to become 
unresponsive. CTLA-4 out competes CD28 and binds to the ligands CD80 and CD86.  CTLA-
4 knockout mice show systemic autoimmune disease which illustrates the importance of 
anergy in preventing autoimmune disease. CTLA-4 has been linked to the development of 
Graves’ disease and type 1 diabetes.  
 The deletion of autoreactive T cells is mediated through apoptosis in the Fas 
ligand pathway. The fas death receptor contributes to the initiation of apoptosis and a 
polymorphism in Fas causes a breakdown in tolerance.  
 Suppression of autoreactive T cells is through Treg T cells. Regulatory T cells that 
are CD4+CD25+ express FoxP3 which has been shown to be important for autoimmunity. 
FoxP3 deficient mice develop systemic autoimmunity disease caused by a decline in 
regulatory T cells. They suppress IL-2 secretion and induce the expression of 
immunosuppressive cytokines IL-10 and TGF-β. The mechanism of how Treg cells 
suppress immune cells, NK cells and antigen presenting cells are still poorly understood 
(Kronenberg and Rudensky., 2005; Rioux and Abbas., 2005; Cooles et al., 2013; 
Rangachari and Kuchroo., 2013). 
 
1.3.2 Autoimmune diseases 
1.3.2.1 Multiple Sclerosis (MS) 
 
 MS is a chronic demyelinating disease caused by a T cell mediated autoimmune 
attack on myelin and contributing inflammatory disease in the white matter of the central 
nervous system (CNS). This causes demyelination lesions and neurone defects. MS is 
described as displaying massive T cell infiltration, loss of conductivity in the axons and 
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dysfunctional neurone activity. MS is a common neurodegenerative disease that becomes 
apparent between the ages of 20-40 years of age and most common in women compared 
with men (Bar-Or et al., 1999; Hemmer et al., 2002; Rangachari and Kuchroo., 2013).  
 
1.3.2.2 EAE Model 
 
 Experimental Autoimmune Encephalomyelitis (EAE) is a mouse model of MS. The 
EAE mouse model is used to study the manifestation of this degenerative disease in mice. 
EAE can be introduced into mice by injection of peptides derived from myelin proteins 
like myelin basic protein (MBP), Myelin oligodendrocyte glycoprotein (MOG) and 
proteolipid protein (PLP). The disease progression course is observed by clinical scoring 
(Bar-Or et al., 1999; Hemmer et al., 2002; Rangachari and Kuchroo., 2013).  
 
1.3.2.3 Myasthenia Gravis 
 
 Myasthenia Gravis is an autoimmune disease that generates autoantibodies to the 
nicotinic acetylcholine receptor that is important at neuromuscular junctions and leads to 
muscle weakness.  The mouse model used to explore this autoimmune disease is 
Experimental autoimmune MG (EAMG) (Sedimbi et al., 2013). 
 
1.3.2.4 Rheumatoid Arthritis 
 
 Rheumatoid Arthritis is caused by a systemic inflammatory disease that is Th1 
driven in synovial joints. It is characterised by chronic inflammation and cartilage damage 
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which further amplifies this disease and causes severe pain (Sedimbi et al., 2013). 
Patients with the disease develop severe joint pain and become less motile. Rheumatoid 
arthritis has been discovered to involve high levels of IgG antibody and autoreactive T 
cells. This is due to the presentation of the autoantigen by the APC and activation from 
pro-inflammatory cytokines (Murphy., 2008).  
 
1.3.2.5 Systemic Lupus Erythramatosus (SLE) 
 
 SLE is a systemic autoimmune disease which is caused by the loss of 
immunological tolerance and allowing the survival of autoreactive T and B cells. 
Depending on the organ type and immune response generated, this can have profound 
effects on the severity of the disease caused. As yet there is no cure for this disease and 
the underlying mechanisms are still unresolved. However, we do know that genetics plays 
an important part in the susceptibility to develop this disease. So far more than 40 genes 
have been recognised to be important for various signalling pathways that are involved. 
The IFN gene has been identified to be closely linked with the severity of SLE patients. 
The IFN genes have been shown to deregulate DNA repair genes, apoptosis, 
inflammation, cell proliferation and cell motility. 
 Indeed genetic factors are important for the susceptibility in developing this 
disease; however environmental factors could also be important. DNA or RNA 
methylation and histone modifications have been shown to be important in causing 
defects or abnormalities in key genes associated with the development of the disease 
(Frangou et al., 2013). 
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1.3.3 Autoimmune disease and chronic inflammation 
 
 Autoimmune disease is generated from a loss of tolerance and the development 
of autoantigens. In general autoimmune disease progresses into chronic autoimmune 
disease due to high levels of autoantigens and chronic inflammation. The chronic 
inflammation leads onto tissue damage and pro-inflammatory cytokines to further cause 
tissue destruction and damage (Murphy., 2008). 
 
1.3.4 Genetic basis of autoimmune disease 
 
 Some genetic defects have been shown to increase the susceptibility to develop 
autoimmune disease, in particular Type 1 diabetes. However multiple gene defects are 
more likely to be the causes for inheritable autoimmune disease. Some single gene 
defects have been identified to cause X-linked recessive autoimmune diseases. For 
example, immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome 
(IPEX) are caused by a single mutation in FoxP3. IPEX patients have severe allergic 
inflammation, diarrhea and early death. In some cases, other genes involved in various 
signalling pathways have been indicated to increase the susceptibility to develop 
autoimmune disease. In this case CTLA-4 for example, if it is mutated it can cause 
hyperproliferation (Murphy., 2008).  
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1.4 Early Growth Response Gene family 
 
 The Early Growth response (EGR) gene family consists of four members EGR-1 
(Zif268), EGR-2 (Krox20), EGR-3 (Pilot) and EGR-4 (NGF1-2) which are transcription 
factors. The EGR family contain three zinc fingers in the DNA binding domain, CyS2-HyS2 
which interacts with target genes rich in GC consensus DNA motifs. The zinc finger 
domain across the four family members display 90% homology so there is a possible 
overlap in binding to target genes. Apart from the DNA binding domain, the activation 
domains and basic domains do not share homology allowing these EGR molecules to 
regulate other signalling pathways and have different functions (Joseph et al., 1988; 
Poirier et al., 2008; Myouzen et al., 2010). 
   EGR-2 was first discovered to be activated early in the G0/G1 stage of the cell cycle 
after serum stimulation in quiescent fibroblast cells; they found accumulating Krox-20 
mRNA (Chavrier et al., 1988). The EGR-2 gene is 2719 nucleotides long and the amino acid 
composition shows it has residues rich in proline (15%), serine (11%), alanine (8%), 
threonine (7%) with a Mr of 43,307. The EGR-2 gene is located on chromosome 10q21. 
Mutations on chromosome 10 are associated with tumors (Joseph et al., 1988; Oehen 
and Brduscha-Riem., 1998; Walzer et al., 2002; Poirier et al., 2008; Myouzen et al., 2010).  
 Early Growth Response genes were first recognised to be critical in hindbrain 
development and long term memory maintenance. EGR-1 in particular has been shown to 
be critical in neural plasticity and demonstrated in EGR-1 deficient mice, showing a severe 
impairment in the hippocampus and long term memory signalling (O’Donovan et al., 
1999; Poirier et al., 2008). Similarly, EGR-3 knockout mice display deficits in learning, 
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memory formation and motor neuron abnormalities.  EGR-3 knockout mice also display 
ataxia (Sumitomo et al., 2013).  
 EGR-2 on the other hand has been shown to be important for peripheral nerve 
myelination and hindbrain development. Complete knockout of EGR-2 causes perinatal 
lethality due to severe defects in hindbrain formation. Therefore, EGR-2 conditional 
knockout mice were developed. For this, EGR-2 was conditionally knocked out of 
forebrain neurons. This group found that the other EGR family members do not play a 
compensatory role when one family member is absent. This group found that EGR family 
members may play opposing roles in brain development (O’Donovan et al., 1999; Poirier 
et al., 2008).  
  EGR-1, EGR-2 and EGR-3 are not only expressed in the central nervous system, 
they are also expressed in many other tissues. However, the fourth member of the EGR 
family, EGR-4, is strictly conserved in the central nervous system. Research has found that 
EGR-4 has a totally different function compared with the other EGR members. Research 
on EGR-4 has found it to be involved in male fertility and regulating leutinising hormone. 
EGR-4 is found to be essential for germ cell maturation. EGR-4 deficient mice show male 
infertility due to apoptosis during early-mid pachytene germ cell development stage 
(Tourtellote et al., 1999; Tourtellote et al., 2000).  
 EGR-1, EGR-2 and EGR-3 are also important for T cell development, tumorgenesis, 
apoptosis, proliferation and anergy (O’Donovan et al., 1999; Poirier et al., 2008). 
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1.4.1 Role of EGR in T and B cell development  
 
 EGR-1, 2 and 3 are all induced upon activation of the pre-TCR, when they are over 
expressed, this can cause deregulation and forced expression into β-selection. EGR-1 is 
the earliest transcription factor expressed after TCR stimulation on DP thymocytes. EGR-1 
and EGR-3 proteins are involved in the progression from the DN3 to the DN4 stage in 
thymocyte development. EGR-1 and EGR-3 promote the survival at the β selection point. 
EGR-3 is known to be involved in the post β- selection proliferation and possibly the most 
critical at this step (Joseph et al., 1988; Shao et al., 1997; Basson et al., 2000; Unoki and 
Nakamura., 2003; Wang et al., 2007; Lauritsen et al., 2008; Fukuyama et al., 2009; 
Lazarevic et al., 2009; Hu et al., 2011).  
 Positive selection in the thymus is governed by the EGR family of proteins and is 
dependent on the Ras/MAPK signalling pathway. EGR-1 over expression forces positive 
selection for low affinity TCR. In contrast EGR-1 deficient mice have impaired positive 
selection with low CD4 or CD8 single positive cells. Similarly when there is a deficiency in 
EGR-1 and EGR-3 they show a significant decrease in CD8 single positive cells as well as 
low CD4 single positive cells. 
 EGR-2 is also important for DP selection as shown in EGR-2 deficient mice where 
they have impairments in CD4 and CD8 lineages. Data has shown that when EGR-2 is 
overexpressed there is an increase in the generation of single positive CD8 thymocytes 
due to low SOCS-1 expression, whereas a deficiency in EGR-2 leads to reduced single 
positive thymocyte numbers. This is due to fluctuations in the expression of survival 
factors and BCL-2 expression in DP cells. Directly EGR-2 has been shown to affect the IL-7 
survival pathway shown when there is a deficiency in EGR-2, there is a block in the IL-7 
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pathway in thymocyte development. Loss of EGR-2 fails to upregulate BCL-2 and 
increases SOCS-1 expression causing a block in IL-7 signalling. Critically levels of EGR-2 will 
permit either positive selection or death by apoptosis (Oehen and Brduscha-Riem., 1998; 
Lauritsen et al., 2008; Lawson et al., 2010). 
 EGR-1 and EGR-2 are important for invariant natural killer T (iNKT) cells which play 
a role in protection against foreign pathogens, tolerance and tumor surveillance. iNKT 
cells develop in the thymus and are a subset made alongside T and B cells. These cells 
derive from the DP T cells. iNKT cells undergo selection through the invariant TCR on the 
iNKT cell with CD1d+ on DP cells. iNKT cells that express functional TCR are positively 
selected and undergo proliferation and development and display NK1.1 on their surface. 
The involvement of calcineurin dephosphorylating NFAT drives the expression of target 
genes critical for T cell development and activation pathway. Mice deficient in a subunit 
of calcineurin have a defect in NFAT dephosphorylation and T cell development. Research 
has found that actually EGR-1 is not critical for iNKT development as EGR-1 knockout mice 
displayed normal NKT development possibly due to compensation from EGR-2. On the 
other hand, EGR-2 deficient mice have severely reduced iNKT cell numbers and were 
unable to mature into fully functional iNKT cells expressing NK1.1, there was a block in 
this transition showing EGR-2 is important.  When both EGR-1 and EGR-2 were knocked 
out, they displayed a severe defect in cell numbers of iNKT cells (Bassiri and Nichols., 
2009; Hu et al., 2011). Also EGR-2 has been shown to bind to Zbtb16 and PLZF adaptors 
which are important for the NKT lineage commitment (Lazarevic et al., 2009; Hu et al., 
2011; Seiler et al., 2012). 
  EGR-2 and EGR-3 are also targets of the CREB binding protein, which are histone 
or protein acetyltransferases important for activating target genes in T cell activation and 
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thymocyte maturation. CREB knockout cells display reduced EGR-2 and EGR-3 expression 
and showed defects in T cell activation and thymocyte development (Fukuyama et al., 
2009).  
 Our group previously have shown that EGR-2-transgenic (EGR-2Tg) mice showed a 
defect in thymocyte development. We found that the size of the spleen was one third 
smaller with increased DN3 and DN4 cells whilst reduced DP cells. On the other hand we 
also examined B cell development and found a defect in EGR-2Tg mice where there was 
an increase in pre-pro B cells (NK1.1-B220+CD19-CD43+)  whilst a decrease in pro-B cells 
(NK1.1-B220+CD19+CD43+), pre-B cells (NK1.1-B220+CD43-)  and immature B cells (NK1.1-
B220+IgM+). Mature B cell numbers were normal, similar to T cells. Interestingly the 
expression of Notch1 and Nur77 genes was severely reduced in ISP cells in EGR-2Tg mice. 
In pro-B cells Pax5 expression was reduced, this gene is important for lineage 
commitment.  This indicated that EGR-2 is strictly controlled during T and B cell 
development where it is expressed early on in development after β-selection in DN cells 
and EGR-2 expression is withdrawn between the ISP and DP thymocyte stage (Li et al., 
2011).  
 
1.4.2 Role of EGR in anergy 
 
 EGR-2 was first discovered to be involved in the immune system after stimulation 
with PMA in human lymphocytes. RNA was extracted and an RNA blot was performed 
which showed high EGR-2 mRNA expression in time points up to 3 hours (Joseph et al., 
1988).  EGR-1, EGR-2 and EGR-3 are expressed only upon B and T cell activation whilst 
EGR-4 is continuously expressed in T cells.  
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 Known target genes of EGR include growth factors like vascular endothelial 
growth factor (VEGF). EGR are modulated through direct interaction from NGFI-A binding 
proteins (NAB) NAB1 and NAB2. More importantly NAB2 has been shown to be more 
important for EGR expression. NAB2 can either repress or activate the expression of the 
EGR family members depending on cell activity. For example upon T cell activation NAB2 
and EGR-1 transactivate the IL-2 promoter vital for full T cell activation and proliferation. 
In other cases, low NAB2 leads to induced expression EGR-2 and EGR-3 which leads to 
anergy. Indeed further evidence has shown that EGR-1, EGR-2 and EGR-3 can also 
positively regulate NAB2 gene expression which plays a role in the negative feedback loop 
to inhibit NAB2 transcription and prevent the prolonged expression of EGR displayed in 
melanoma cell lines. They showed EGR-1, EGR-2 and EGR-3 upregulate NAB2 expression 
and EGR-1 can positively regulate EGR-2 and EGR-3 transcription. EGR-3 can further 
enhance EGR-2 expression showing that these two transcription factors interplay with 
each other (Shao et al., 1997; Poirier et al., 2008; Kumbrink et al., 2010; Myouzen et al., 
2010).  
 Anergy induction is believed to involve NFAT as EGR-2 is the target gene. De-
phosphorylated NFAT can enter into the nucleus to promote the transcription of genes 
mediating T cell activation and anergy. NFAT also can transactivate the other members of 
the EGR family including EGR-3. EGR targets include E3 ligases GRAIL, cbl-b and Itch, 
which are important in anergy (Rengarajan et al., 2000; Safford et al., 2005; Bassiri and 
Nichols., 2009; Arias et al., 2010; Kumbrink et al., 2010; Myouzen et al., 2010; Okamura et 
al., 2010). 
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 1.4.3 EGR-2 and EGR-3 role in Autoimmunity  
 
 Autoimmunity is largely caused by a breakdown in tolerance. The Treg T cells are 
important for preventing autoimmune disease. Treg cells express FoxP3 and mice that 
have a deficiency in this transcription factor develop lymphoproliferative characteristics 
and inflammatory immunopathology. Data has shown that the IL-10 regulatory T cells, 
CD4+CD25-LAG3+ express EGR-2 and shows that EGR-2 is important for the development 
of this subset. Overexpression of EGR-2 increases the susceptibility for systemic lupus 
disease caused by a breakdown in tolerance and loss of T regulatory T cells (Okamura et 
al., 2009; Myouzen et al., 2010; Gao et al., 2012). 
 Previously our group have shown that in EGR-2cKO mice where the EGR-2 gene 
has been specifically knocked out in the CD2+ lymphocytes, they displayed lupus-like 
autoimmune disease in older mice (Zhu et al., 2008). The mice displayed huge 
lymphocyte infiltration in the liver, kidney and spleen along with IgG deposits in the 
glomerulus (Zhu et al., 2008). The EGR-2 deficient T cells were hyper-proliferative when 
given sustained antigen stimulation. They displayed high levels of the activation markers 
IFN-γ, CD69 and infiltrating levels of pro inflammatory cytokines IL-17A and IL-17F (Zhu et 
al., 2008). EGR-2 deficient T cells also displayed an accumulation of memory phenotype 
CD44 T cells compared to young mice. In fact the hyper-proliferation displayed in our 
EGR-2 knockout mice was due to defective expression of p21cip1, as EGR-2 directly 
activates the p21cip1 promoter (Zhu et al., 2008).  Tolerant cells display p21cip1 and loss 
of p21cip1 causes hyper-activation and proliferation in T cells. This demonstrates that 
EGR-2 is important for the intrinsic control of proliferation where the loss of EGR-2 leads 
to a huge accumulation of T cells to self-antigens (Zhu et al., 2008).   
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1.5 Aims of Study  
 
 The role of the EGR family has been well established in the CNS system with these 
transcription factors to be critical for myelination. Furthermore our group have previously 
established a CD2 specific EGR-2 conditional knockout mouse model to study the role of 
this transcription factor in lymphocytes.  EGR-2cKO mice develop lupus-like autoimmune 
disease and high secretion of pro-inflammatory cytokines (Zhu et al., 2008). Despite 
lupus-like autoimmune disease, lymphocyte proliferation was normal after mitogenic 
stimulation. To study further the function of EGR-2 in lymphocytes, we generated a CD2-
EGR-2-/-EGR-3-/-mouse model, therefore, the aims of this study were:  
1. Establish CD2-EGR-2-/-EGR-3-/-mice model. 
2. To investigate the phenotype of CD2-EGR-2-/-EGR-3-/-mouse model.  
3. To study the susceptibility of developing autoimmune disease pathology by 
inducing EAE disease in CD2-EGR-2-/- mice.  
4. To measure cell proliferation in CD2-EGR-2-/-, EGR-3KO and CD2-EGR-2-/-EGR-3-/- 
mice.   
5. To identify the molecular mechanism of the T cell receptor signalling pathway 
using molecular biology techniques. 
  
 In conclusion, the hypothesis of my research is that EGR-2 and EGR-3 are critical 
for controlling inflammatory mediated autoimmune disease and intrinsically regulates 
lymphocyte activation in response to mitogenic stimulation.  
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Chapter 2: Materials and Methods  
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2.1 Mouse Models 
 
2.1.1 EGR-2 Conditional Knockout mice 
 
 EGR-2 LoxP/LoxP and hCD2 Cre transgenic mice were gifts from Dr P. Charnay, 
Institute National de la Santé et de la Recherche Médicale, Paris, France; they were 
crossed together to create the EGR-2 conditional knockout (EGR-2cKO) mice. The Cre 
insertion and recombination at the two LoxP sites for the EGR-2-transgene were detected 
in Cre expressing lymphocytes only. Mice were crossed at least three times on C57BL/6 
background. The EGR-2cKO mice were maintained in the Biological Services Unit, Brunel 
University and used in accordance with the institution guidelines under the U.K Home 
Office project license. Verification of Egr-2cKO mice was carried out by genotyping on tail 
DNA, for identification of the EGR-2 loxP and iCre loci by Polymerase Chain Reaction (PCR) 
analysis (See Table 1 for primer list).  Cre and LoxP specific primers were used in PCR 
analysis on genomic tail DNA to detect the presence of both the knockout alleles. The 
PCR products of knockout were Cre 150 bp and Loxp 210 bp or the Wild Type (WT) allele 
of 195 bp. The selection of the knockout alleles with Cre and LoxP were used to generate 
the EGR-2cKO mice. 
   
2.1.2 EGR-3 Knockout mice 
 
 We obtained EGR-3 KO under C57BL background mice from St Louis, Missouri 
(Tourtellotte and Milbrandt., 1998). To confirm genomic deletion of EGR-3, we carried 
out genotyping with two primer pairs specifically either to the knockout or WT alleles as 
shown in Table 1 primer list. The PCR products of knockout allele were 735bp, while WT 
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was 350bp. The mice were maintained in the Biological Services Unit, Brunel University 
and used in accordance with the institution guidelines under the U.K Home Office project 
license.  
 
2.1.3 EGR-2 Transgenic mice 
 
 CD2-specific EGR-2 transgenic (EGR-2Tg) mice were established as previously 
described by our group (Li et al., 2011). Briefly primers were designed for the EGR-2 
coding regions and EcoRI flanking regions from the EGR-2 expression construct. PCR was 
performed to amplify those products and then cloned into the vector containing the 
human CD2 promoter and injected into fertilised C57/BL/6 oocytes (Li et al., 2011).  The 
detection of the CD2-specific EGR-2Tg mice was performed by genotyping of tail DNA by 
PCR. The primers listed in table 1, were used for PCR analysis and the correct product size 
was 350bp. 
 
2.1.4 Genotyping mouse tail DNA by PCR 
 
 Mouse tails were collected and prepared with REDExtract-N-Amp Tissue PCR Kit 
(Sigma) in accordance with the manufacturer’s protocol.  Mice were identified using PCR 
to selectively amplify exponential DNA sequences. This technique uses the thermostable 
DNA polymerase from Thermus aquaticus (Taq) that works at exceedingly high 
temperatures. As this process is specific, sense and antisense primers for EGR-2 knockout 
alleles, EGR-3 knockout alleles and EGR-2Tg alleles at a final concentration of 0.5μM were 
used as shown in Table 1. The PCR series of sequences denaturation, annealing and 
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extension were carried out under specific cyclic conditions as shown in Table 1. The PCR 
products were observed by Agarose Gel Electrophoresis at 100V in TAE Buffer (Sigma). 
The gel was visualized under ultraviolet (UV) light by the Alpha Imager. 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Table 1: Showing Primers and PCR cycle information for Genotyping 
 
 
huCD2-EGR-2 Transgenic Sense Sequence CCA CCA GTC TCA CTT CAG TTC C 
 Antisense 
Sequence 
CAG CTG CTG CAG AAA ACC ACT G 
 
 
PCR cycle 
95˚C for 5mins 
94˚C for 40 sec 
55˚C for 40sec         30cyc 
72˚C for 40sec  
72˚C for 5mins 
Keep in 4˚C 
hCD2 EGR-2 KO LoxP Sense Sequence AGT TGA CAG CCC GAG TCC AGT GG 
 Antisense 
Sequence 
GGG AGC GAA GCT ACT CGG ATA CGG 
 
 
PCR cycle 
95˚C for 5mins 
94˚C for 40sec 
65˚C for 40sec         30cyc 
72˚C for 40sec 
72˚C for 5mins 
Keep in 4˚C 
hCD2 EGR-2 KO Cre Sense Sequence CCA ACA ACT ACC TGT TCT GCC G 
 Antisense 
Sequence 
TCA TCC TTG GCA CCA TAG ATC AGG 
 
 
PCR cycle 
95˚C for 5min 
94˚C for 40sec 
56˚C for 40sec           30cyc 
72˚C for 40sec 
72˚C for 5min 
Keep in 4˚C 
EGR-3KO Neo Sequence GAT TGT CTG TTG TGC CCA GTC 
 Sense Sequence CTA TTC CCC CCA GGA TTA CC 
Antisense 
Sequence 
TCT GAG CGC TGA AAC G 
 
 
PCR cycle 
95°C for 2mins 
95°C for 30sec 
57°C for 30sec          35cyc 
72°C for 30mins 
72°C for 30mins 
4°C for 10sec 
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2.2 Cell Line 
 
 The Human Embryonic Kidney 293 (HEK293) cell line (sourced by Barts London 
School of Dentistry and Medicine) was generated in the 1970’s by transformation of 
HEK293 cells with adenovirus 5 DNA. The Human Embryonic Kidney cells were derived 
from a healthy fetus. This cell line has been extensively used in cell culture as they grow 
quickly and can be easily transfected. The cell line was maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% FBS (Fetal Bovine Serum), 50 μM 2-
mercaptoethanol (2-ME), and 100 U/ml penicillin and 100 μg/ml streptomycin (all 
purchased from Invitrogen). Culturing cells were kept in a humidified incubator with 5% 
(v/v) carbon dioxide at 37 °C at a density of 1 x 106 per ml. 
 
   2.3 Antibodies and Flow Cytometry 
  2.3.1 Antibodies  
 
 Fluorescein isothiocyanate (FITC) conjugated antibody used was IFN-γ. The 
phycoerythrin (PE) conjugated antibodies used were BrdU, CD3, CD4, CD8, IL-17A and 
IgM. The above antibodies and CD3 (clone 145-2C11) and CD28 (clone 37.51) stimulation 
antibodies with 7AAD were obtained from BD Biosciences.  
 Also we used antibodies specifically for western blot and immunoprecipitation. 
The anti-Batf antibody was obtained from Santa Cruz Biotechnology. EGR-2 and EGR-3 
were purchased from Covance and Santa Cruz Biotechnology. The IgM stimulation 
antibody containing the F(ab’)2 fragments of goat anti–mouse was from Jackson 
ImmunoResearch Laboratories, Inc. The FITC-conjugated donkey anti-mouse IgG and 
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Alexa Fluor 594-conjugated donkey anti-rabbit IgG secondary antibodies were purchased 
from Jackson Immunoresearch. The pErk42/44, myc-tag, flag-tag and histone-3 were 
from Cell signalling Technology. The anti-Erk, Rabbit anti-c-Fos, Mouse anti-Jun B, c-Jun, 
and anti-Batf were obtained from Santa Cruz. 
 
2.3.2 Flow Cytometry  
 
 Flow Cytometry was used to identify cell surface and intracellular markers on T 
and B cells from a population of cells using the LSRII (BD Immunocytometry Systems). The 
data was analysed using the FlowJo software. Also cell sorting for successfully transfected 
positive cells was done on the FACSAria sorter with the DIVA option (BD 
Immunocytometry Systems).  
 
2.3.3 Intracellular Cytokine staining 
 
 Splenocytes were stimulated with PMA (20 ng/ml) and ionomycin (0.5 μg/ml) with 
the addition of Brefeldin A for 5 hours at the end of stimulation. The cell surface markers 
were stained next followed by the intracellular staining using the Fixation and 
Permeabilization Kit for IFN-γ and IL-17A according to the manufacturers protocol 
(Ebioscience).  
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2.4 Preparation of plasmid construct into Lentiviral vector 
2.4.1 Lentiviral vectors 
 
 Lentiviruses are a type of retrovirus that is used to deliver large quantities of viral 
RNA into the DNA of host cells for stable expression of a desired gene. Therefore these 
retroviruses are useful for facilitating the production of endogenous proteins in the host 
cell. Primarily retroviruses contain three main types of viral genes, Gag, Pol and Env that 
are used for the effective transfer of the gene vector whilst not producing pathogenic 
particles. The gene of interest to be integrated into the host genome is sequenced to be 
inserted in-between the two Long Terminal Repeat (LTR) regions of the virus. The LTR is a 
sequence of DNA that facilitates the integration of the viral DNA into the host genome.  
 
2.4.2 Amplification of mouse cDNA for cloning 
 
 Mouse cDNA for EGR-2 and Batf were tagged with Myc and Flag (Plasmid 
construct and cDNA sequence obtained by Dr T.Miao, Barts and the London School of 
Dentistry and Medicine) and amplified using PCR to be able to produce enough cDNA 
required for ligation and transformation. The following reagents used for PCR were 
purchased from Invitrogen, 10xPfx Amplification Buffer, 10x Enhancer Buffer, 50mM 
MgSO4, 10mM dNTP, primers for the cDNA and Pfx DNA Polymerase according to the 
manufacturer’s protocol. The PCR cycle was carried out following denaturation, annealing 
and extension for 35 cycles specified in the manufacturer’s protocol.  
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2.4.3 Restriction Digestion, Ligation and Transformation 
 
 The cDNA was first digested with the appropriate digestion enzyme for correct 
incorporation into the bacteria at 37°C for 80 minutes. Once this was done, the mouse 
cDNA and competent bacteria were incubated together for the process of ligation. The 
bacteria construct used was, NEB 10-beta Competent E. coli (C3019) cells, this type of 
bacteria construct was used as it is highly efficient for transformation and can uptake 
large plasmid vectors. The process of ligation covalently links two ends of DNA together. 
The reagents used for ligation were vector backbone, 10x ligase buffer and T4 ligase 
enzyme (New England BioLabs) and incubated for 15 minutes at 70°C. Transformation 
was then performed on the ligation products with the competent bacterial cells by the 
freeze-thaw method. Transformation is a process involving bacterial uptake of exogenous 
DNA from its surroundings.  
 The freeze-thaw method creates a tension on the cell membrane and perforates it 
to allow the DNA to be taken up. The process involved the ligation products and 
competent cells to be placed on ice for 5 minutes, followed by heat pulsation at 42°C for 
30 seconds and then placed on ice again for a further 5 minutes. The cells were allowed 
to recover by incubating them with Super Optimal broth with Catabolite repression 
(SOCS) medium (Sigma) in 37°C for 1 hour at 225rpm. SOCS medium is a nutrient rich 
growth medium with added glucose that improves the transformation efficiency. 
Following this, the cells were placed on a Luria-Bertani (LB) solid Agar plate (10g/L NaCl, 
10g/L Tryptone, 5g/L Yeast Extract, 2g/L Agar) supplemented with ampicillin antibiotic at 
100µg/µl for antibiotic growth selection.  
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2.4.4 Mini-Prep culture and identification of correct plasmid by separation on a 0.7% 
Agarose Gel 
 
 Single colonies from the agar plate were grown overnight in a small volume of  LB 
broth (10g/L NaCl, 10g/L Tryptone, 5g/L Yeast Extract) supplemented with ampicillin 
antibiotic at 100ng/µl and incubated at 37°C at 225rpm. Selective colonies were grown 
and mini-prep was done using the mini-prep kit from Qiagen according to the 
manufacturer’s protocol, for identifying the correct incorporation of the plasmid. Briefly, 
the addition of P1, P2 and N3 buffers precipitate the DNA and protein into a clear lysate. 
The lysate was then passed through a silica-gel membrane, coated with PB buffer 
containing high salt. When the DNA passes through the column it attaches to the 
membrane. The column was washed with a PE buffer to discard protein, RNA etc. from 
the lysate. To elude the DNA a low salt buffer, EB was used. Purified DNA was then 
eluded and plasmid DNA concentration quantified using the Nano-drop.  
 
2.4.5 PCR amplification and separation by Electrophoresis on an Agarose Gel 
 
 This method specifically amplifies the desired gene from a high proportion of 
undesired plasmid DNA by PCR. The reagents required were, forward and reverse 
primers, the template DNA, 10mM dNTP’s polymerase buffer and polymerase enzyme. 
The PCR products were run on a 0.7% Agarose gel to check the PCR product size. The 
correct product was then excised and gel purified using the Qiagen kit to remove 
unwanted PCR debris and undesired plasmid DNA.  
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2.4.6 Restriction Digestion and separation by Electrophoresis on an Agarose Gel 
 
 Restriction digestion was used to identify that the plasmid had been successfully 
incorporated and that the orientation and position of the insertion was correct. 
Restriction enzymes were selected from the restriction sites surrounding the point of 
plasmid insertion into the vector. A restriction digestion was performed from the 
manufacturer’s guidelines (New England Biolabs). The products were heated at 65°C for 1 
hour and then separated by electrophoresis on a 0.7% Agarose Gel. 
 
2.4.7 Midi-Preparation 
 
 Plasmids that contained the correct orientation were selected and grown in a 
larger volume LB broth supplemented with Ampicillin and grown overnight in 37°C at 
225rpm on a larger scale. Midi-preparation was performed according to the 
manufacturer’s protocol from Qiagen. The protocol used in mini-prep is similar to the 
midi-prep protocol. However, in this case, large quantities of plasmid can be purified. 
Briefly, the buffers P1, P2 and P3 precipitated the DNA into a clear lysate. The lysate was 
then passed through the qiagen tip which further precipitates protein out, leaving the 
lysate containing DNA. The lysate was then passed through the silica membrane where 
the DNA binds to the column. The wash steps using QC buffer removes any contaminants. 
The DNA was eluded using the QF buffer containing low salt. The DNA was quantified 
using the Nano-drop. 
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2.4.8 Production of viral particles and Transduction into packaging cell line  
 
 The viral gene products, gag, pol, env and pcDNA3 expression vector were 
transfected into the packaging cell line HEK293 using Lipofectamine plus reagent (Gibco) 
catalogue number 15338100 for 4 hours at 37°C. Once the vector is inside the cell and 
transcription begins, the gag, pol, and env genes along with ψ present in the viral RNA, is 
used to compose the virion particles which bud off from the cell. The viral particles are 
therefore in the supernatant, so after 48 hours the supernatant was collected and viral 
particles harvested by ultracentrifugation. The virus titre was quantified to 109 
transducing units per ml. The viral particles were then used to infect the target cell line 
HEK293. Batf and EGR-2 expression levels were confirmed by immunohistochemistry and 
immunoblotting with the antibodies to Myc and Flag. 
 
2.5 Real-Time PCR (RT-PCR)  
 
 Total RNA was extracted from CD4+ T cells or B cells were either unstimulated or 
stimulated, using the RNeasy Kit purchased from Qiagen. The RNeasy kit does not use the 
phenol/chloroform method and does not cause ethanol precipitation; it allows easy and 
pure extraction of RNA. This kit separates RNA from proteins and DNA and the method 
followed was according to the manufacturer’s protocol. Briefly, cells were pelleted and 
lysed using guanidine-isothiocynate which denatures proteins prior to purification in the 
column. Ethanol was added to coat the RNA structures so that it would bind to the silica 
membrane spin column. The RNA would bind to the column and other components such 
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as DNA and protein would be removed in the washing steps. The pure RNA was then 
eluded using water.  
 Pure RNA was then reverse transcribed into cDNA using a reverse transcriptase 
enzyme that makes a complementary cDNA strand from the RNA template. This method 
uses Oligo (dT) primers from Amersham, Biosciences that bind to the poly-A tails of the 
mRNA acting like primers and initiates revere transcription.  
 The resulting cDNA was then subjected to qRT-PCR which is similar to the PCR 
technique however; this method measures the mRNA transcripts (gene expression) from 
tissues in real time compared to conventional PCR where products are measured at the 
end.   
 The RT-PCR method measures the fluorescence of SYBR green which is emitted 
after each cycle of PCR and enables you to directly quantify mRNA expression. The 
melting temperature (Tm) was also determined for each sample to establish where there 
is 50% denaturing of the DNA to identify non-specific binding. The Tm was calculated 
using: Tm= 4 x [G + C] + 2 x [A + T]. The reagents used were from the QuantiTect SYBR 
Green PCR kit (Qiagen) according to the manufacturer’s protocol and used at a 
concentration of 1μl cDNA and 0.2μl sense and anti-sense primers as shown in Table 2. 
This method was performed on the Rotor-Gene System (Qiagen, Corbett Robotics) and 
the data interpreted using the Rotor-Gene Software. The program for qRT-PCR consisted 
of denaturing, annealing and extension steps. The cycle threshold (Ct) was calculated for 
each sample and measured the number of cycles of the fluorescent signal that is required 
to reach the threshold level. The Ct value is inversely proportional to the quantity of 
nucleic acid that is generated; therefore a high Ct value would mean a lower proportion 
of nucleic acid generated. Each sample was run in duplicate and the relative mRNA 
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expression levels were normalized against the expression levels of β-actin from the same 
samples, under the same program. It was worked out by: Relative expression= 2^(CTβ-
actin-CT target)*10,000. 
 
Gene  Sense 5’-3’ Antisense 5’-3’ 
EGR-2  CTTCAGCCGAAGTGACCACC 
 
GCTCTTCCGTTCCTTCTGCC 
EGR-3  CGACTCGGTAGCCCATTACAATCAA GAGATCGCCGCAGTTGGAATAAGGG 
β-actin AATCGTGCGTGACATCAAAG ATGCCACAGGATTCCATACC 
IL-2  GCATGTTCTGGATTTGACTC CAGTTGCTGACTCATCATCG 
IL-17A AGCGTGTCCAAACACTGAGG CTATCAGGGTCTTCATTGCG 
IFN-γ CCATCAGCAACAACATAAGC AGCTCATTGAATGCTTGGCG 
IL-21 ATCCTGAACTTCTATCAGCTCCAC GCATTTAGCTATGTGCTTCTGTTTC 
IL-4 CAAACGTCCTCACAGCAACG CTTGGACTCATTCATGGTGC 
GM-CSF TGGTCTACAGCCTCTCAGCA CCGTAGACCCTGCTCGAATA 
Batf GAGCTGCGTTCTGTTTCTCC CCAGAAGAGCCGACAGAGAC 
Table 2: Real-Time PCR Primer sequences 
 
2.6 Measuring Proliferation using (3H)TdR incorporation or BrdU  
 
 This technique was performed by Dr T. Miao, Barts and the London School of 
Dentistry and Medicine, London, where I was also actively involved.   
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WT and K2/3 mice CD4 or B cells were isolated and plated at 5 x 104 cells/200µl in 96 well 
plates in triplicate. To measure proliferation in the cells 1µl Cl (3H)TdR (tritiated 
thymidine) was added to the last 8 hours of culture before harvesting. TdR is a thymidine 
nucleotide that has radioactively labelled hydrogen called tritium (3 H). The active 
incorporation of this thymidine occurs when cells are undergoing DNA synthesis, so it is a 
good marker for proliferation. The cells were then subjected to Scintillation which 
involves the conversion of radioactive emissions from (3H)TdR, when being incorporated 
into newly synthesized DNA, into sparks of light. (3H)TdR is measured in a Scintillation 
counter that contains fluor liquid, which converts the radioactive β-emissions into light 
and records as counts per minute.  
 Another way to observe proliferation is using BrdU (Bromodeoxyuridin). Like 
(3H)TdR, BrdU is incorporated into newly synthesised DNA. BrdU when incorporated into 
newly synthesised DNA replaces thymidine with bromodeoxyuridine. BrdU incorporation 
can only be detected with an anti-BrdU antibody. 10μM BrdU was added in the last hour 
of cell culture before harvesting. The cells were stained with PE-conjugated anti-BrdU 
antibody and 7AAD using the manufacturers protocol from the BrdU flow kit, BD 
Biosciences. BrdU incorporation in T cells was measured by Flow Cytometry.  
 
2.7 Nuclear Extraction and Immunoprecipitation 
2.7.1 Nuclear protein extraction 
 
 Stimulated and unstimulated K2/3 or WT CD4 or CD8 T cells were harvested after 
three days. Lysis buffer containing Tris (tris(hydroxymethyl)aminomethane) 10mM, KCL 
60mM, EDTA (ethylenediaminetetraacetic acid) 1mM, DTT (dithiothreitol) 1mM, 0.1% 
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Np40 (Tergitol-type NP-40), PMSF (phenylmethylsulphonyl fluoride) 100nM was added to 
the cell pellet and incubated for 5 minutes on ice to lyse the cytoplasmic membrane. The 
Lysis Wash Buffer containing Tris 10mM, KCL 60mM, EDTA 1mM, DTT 1mM, PMSF 
100nM, was added and spun down at 1200rpm for 5 minutes to remove debris. The 
cytosolic protein in the supernatant was kept and further washed with Lysis Wash Buffer 
to remove contaminants. The pellet was then re-suspended in Nuclear Lysis Buffer 
containing Tris-CL 50mM, EDTA 10mM, 0.8% SDS (Sodium dodecyl sulphate), PMSF 1mM 
and protease inhibitors (Roche) and incubated for 30 minutes on ice to lyse the nuclear 
membrane. The cells were centrifuged at 13,000rpm for 10 minutes to pellet the nuclei. 
The nuclear protein was kept from the supernatant and stored in aliquot at -180°C.  
 
2.7.2 Co- Immunoprecipitation 
 
 Co- Immunoprecipitation is a technique used to examine protein-DNA interactions 
where you can identify transcription factor/DNA binding interactions of interest. Briefly 
fusion proteins with an affinity tag were used to precipitate the target protein and 
purified using immobilized protein A beads.  
  Each precipitation contained 400µl 1x chip buffer (40µl 10x Chip buffer, 360µl 
water, 2µl Proteinase inhibitor cocktail) and 100µl of each sample (500mg chromatin). 
500µl of diluted chromatin, Protein A beads, immunoprecipitation antibodies anti-Myc 
for Batf, anti-Flag for EGR-2 were incubated overnight.  
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Tubes were placed on a magnetic rack and supernatant removed. Washes of low 
salt and high salt were performed to remove non-specific binding to the Protein A beads 
and chromatin eluded.  
 
2.8 Western Blot  
2.8.1 SDS-PAGE Electrophoresis 
 
 The samples were prepared for SDS Polyacrymalide gel Electrophoresis (PAGE) 
which separates proteins through an electric field based on protein size and charge. The 
proteins travel from the negative to positive terminal and the smaller the protein, the 
faster it will migrate through the electric field compared with a larger protein.  
  The samples were prepared prior to denaturing using 4x LDS (lithium dodecyl 
sulfate) sample buffer, β-mercaptoethanol and the reaction heated in 70°c for 10 minutes 
at 900rpm. The samples were run along with a Rainbow molecular marker (Novex) on a 6-
12% SDS PAGE gel composed of a 10% resolving gel containing 10% acrylamide (0.26% 
bisacrylamide solution (Protogel), 0.1% SDS, 0.1% APS (Ammonium Persulphate), 0.04% 
Temed (N,N,N’N’-tetramethylethylene diamine) and 380mM Tris pH8.8), 5% stacking gel 
containing 5% acrylamide (0.13% bisacrylamide solution (Protogel), 0.1% SDS, 0.1%  APS, 
0.1% Temed and 187.5mM Tris pH6.8). The gel was placed in SDS running buffer 1L which 
contained: 50ml SDS and add up to 1000ml with distilled water used for separating the 
protein bands. Samples were run at 150v for 1hr 30 minutes to resolve proteins that are 
closer together.  
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2.8.2 Western Blot Transfer 
 
 After gel electrophoresis the gel was prepared for protein transfer onto a 
nitrocellulose membrane. The transfer was prepared as a stack; four pre-soaked foams in 
Western Transfer Buffer (10ml methanol, 10ml Transfer buffer (Amersham)) were placed 
on the bottom. The gel was placed on the top of the nitrocellulose membrane 
(Amersham), as proteins migrate from the negative to positive terminal and held with 
filter paper that sandwiched it together. The filter paper was required to assist the buffer 
flow once a voltage is applied between the gel and the membrane. Finally, the transfer 
sandwich was stacked with more foam to keep the transfer moist and compact. All of the 
components were pre-soaked in Western Transfer buffer. The sandwich was then placed 
in a cassette containing the Western Blot transfer buffer and transfer was allowed to take 
place at 30v for 1hour 30 minutes. The proteins will transfer onto the nitrocellulose 
membrane at the same position as on the gel.  
 
2.8.3 Blocking, primary antibody, washing, second antibody and developing  
 
 The membrane was placed in 5% blocking buffer containing 5% skimmed milk and 
TBST (Tris Buffered Saline and 0.1% Tween 20) to prevent any non-specific antibody 
binding. The primary antibody as described section 2.3.1 was prepared in 5% BSA 
overnight at 4°C. The membrane was washed to remove unbound primary antibody with 
1xTBST (1M Tris, 5M NaCl, 0.5M EDTA pH8 and distilled water) for 15 minutes, then a 
further three times with TBST for 5 minutes. The membrane was then incubated with the 
second antibody conjugated with IgG HRP (horseradish peroxidase) corresponding to the 
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species of primary antibody (Biorad) for 1 hour at room temperature. The membrane was 
washed 1x TBST for 15 minutes and a further three times in TBST for 5 minutes to remove 
unbound secondary antibody.  
 To detect fusion proteins, chemiluminescense from the ECL prime Western 
Blotting Detection Reagent kit (Amersham) was used according to the manufacturer’s 
protocol. The kit contains detecting reagents that are involved in the oxidation of cyclic 
diacylhydrazides like luminol which produces light when catalyzed by HRP. The detection 
reagents are exposed to the nitrocellulose membrane for 5 minutes to detect peak light 
signals. The luminescence signal was identified by exposure from photographic paper 
(Amersham) over the nitrocellulose membrane.  
 
2.9 Electrophoretic Mobility Shift Analyses (EMSA)  
 
This technique was performed by Dr T. Miao, Barts and the London School of 
Dentistry and Medicine, London, where I was also actively involved. The EMSA technique 
is used to detect protein binding interactions to a DNA sequence labelled by a radioactive 
isotope. The reaction mixture is then run on a non-denaturing polyacrylamide gel. 
Successful binding of the proteins to the radioactively labelled DNA sequence will hinder 
the migration of this complex through the gel. To find specifically whether a protein is 
involved in a protein complex, the addition of an antibody is used to do a supershift 
assay. If the desired protein is part of the complex, the antibody that it binds to will 
further hinder the migration of the complex causing a supershift phenomenon.  
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2.9.1 Labelling the probe 
 
 The following probes were made in Barts and the London School of Dentistry and 
Medicine, London. The consensus probes for AP-1 (50-AGCTTCGCTTGATGAGTCAGCCG-
30),NFkB (50-CAGAGGGGACTTTCCGAGA-30), SP1 (50-ATTCGATCGGGGCGGGGCCAG-30) 
and NFAT (50- CTGTATCAAACAAATTTTCCTCTTTGG-30) were labelled with [a-32P] dCTP 
using Ready-to-Go DNA labeling beads (Amersham Biosciences UK Ltd., Pollards Wood, 
Bucks). 1pmol/µl double stranded primer 2µl,10x Klenow Reaction buffer 
2µl,Radiolabelled dCTP 3µl,0.5mM each dGTP, dATP, dTTP.1µl 5U/µl Klenow 
1µl,Molecular Biology water 11µl were prepared and incubated at room temperature for 
40 minutes. The reaction was stopped by adding 1µl of 0.5M EDTA; this was followed by 
adding 30µl water. Then 40µl sense and antisense primers (dissolved at 100pmol/µl),10μl 
10x annealing buffer (200mM Tris,10mM EDTA, 500mM NaCl pH 8) were added together 
and heated to 95°C for 5 minutes and then left to cool overnight. The reactions were 
placed at 4°C for 2 hours and then stored at -20 °C. 2pmol was used for labelling.  
 The labelled probe was purified using the Qiagen nucleotide removal kit in 
accordance with the manufacturer’s protocol. It contains a silica membrane which single 
nucleotides bind to the column in the high salt buffer conditions in the first binding step. 
The second step involves the washing phase where any impurities are flushed through 
the column. Lastly the elution step involves the collection of the labelled probe under low 
salt conditions.  
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2.9.2 Binding Reaction 
 
 Nuclear extracts from lymphocytes were stimulated with anti-CD3 and anti-CD28 
for T cells or IgM for B cells for 24 hours and restimulated for a further 30 minutes.  The 
cells were incubated with the binding reaction reagents 5x Binding buffer, 20% glycerol, 
5mM MgCl2, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 50mM Tris (pH 7.5), 0.25mg/ml 
poly(dI-dC), labelled probe, nuclear extract and water. The reaction tubes were incubated 
on ice for a further 20-40 minutes. Then 1μl 10xLB was added. For supershift reactions 
anti-Batf, anti-Myc, anti-cFos and anti-JunB antibodies were added in the first 10 minutes 
during the labelling time.  
 
2.9.3 Gel Electrophoresis and Developing 
 
 The samples were run on a 6% Novex DNA retardation gel (30% Acrylamide 1ml, 
10x TBE 300µl, 10% APS 100µl, TEMED 20µl, Water 4.6ml). 0.53xTBE was used in the 
running buffer and run for 30-60 minutes at 100V. The gel was dried for 40 minutes in a 
preheated gel dryer. The cassette was placed in x-ray film in dark room and exposed 
overnight at -80°C and analysed on a Storm 860 PhosphorImager (Molecular Dynamics). 
The intensity of the AP-1 band was normalized against the activity of the SP1 control. 
 
2.10 Messenger RNA Silencing  
 
 This technique was performed by Dr.T.Miao at Barts and the London School of 
Dentistry and Medicine, where I was actively involved. RNAi also termed post-
 69 
 
transcriptional gene silencing is a technique used to silence the expression of genes to 
find out their function etc. Double stranded RNA is synthesized in the cell and will contain 
a sequence complementary to a gene you wish to silence. The long double stranded RNA 
is cut by the enzyme Dicer into short siRNA segments and made single stranded. One of 
the strands is termed the passenger strand which gets degraded and the other is the 
guide strand. The guide strand forms complementary base pair binding with the mRNA 
and is cleaved so it cannot be translated into protein in the RNA-induced silencing 
complex (RISC). The siRNA was made against the mRNA sequence of BATF, EGR-2 and 
EGR-3: siBatf 2, 50-GAACGCAGCUCUCCGCAAA-30; siBatf 4, 50-
GGACUCAUCUGAUGAUGUG-30, siEgr2-1, GCUGCUAUCCAGAAGGUAU-30; siEGR2-2, 50-
CGACCUCGAAAGUACCCUA-30, and siEGR3-1, 50-GCGACUCGGUAGCCCAUUA-30; and 
siEGR3-2, 50-GCAGUUUGCUAAAUCAAUU-30, were created. Non-specific short random 
siRNAs from QIAGEN, CAT: 1027281, were used as negative controls.  
 Primary naïve CD4+ T and resting B cells isolated from 4 week old mice were 
transfected with Amaxa Nucleofector according to the manufacturer’s protocol using 1 
mM siRNA. The Batf siRNA2 sustained specific reductions in Batf expression for at least 72 
hrs from RT-PCR results.  
 
2.11 Histology 
  
 Histology was performed by Dr T.Miao, Barts and the London School of Dentistry 
and Medicine.  Briefly the tissues were fixed with 10% formalin in PBS to retain the tissue 
structures and dehydrated prior to paraffin embedding by adding increasing 
concentrations of ethanol over a period of 5 hours. Then xylene and paraffin wax was 
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added and tissues mounted on a slide pre-coated with gelatin for adherence, and air-
dried overnight in an oven. The Paraffin sections were then deparaffinised to rehydrate 
the tissue section using xylene, followed by reducing concentrations of ethanol. The 
slides were then submerged in blocking buffer 3% BSA and primary antibodies were 
added. Then a second antibody was used and counterstained with DAPI, or sections were 
stained with haematoxylin and eosin. 
 The analysis of urine proteins (proteinuria) was done using urinalysis reagent 
strips (Access Diagnostics Tests, UK) according to the manufacturer’s protocol.  
 To determine the aggregation of Ig deposits 6μm frozen kidney sections were 
obtained and stained with Texas Red conjugated anti-mouse IgG obtained from Jackson 
Immunoresearch Research.  
 
2.12 ELISA 
 
 Performed by Dr T.Miao, at Barts and the London School of Dentistry and 
Medicine, London, where I was also actively involved. Enzyme Linked Absorbent Assay 
(ELISA) is a technique used for the detection of an antigen in a given sample. The process 
initially begins with immobilization of the sample by adding a capture antibody specific 
for the antigen, thus causing the antigen to attach on the surface. Non-specific binding to 
the surface is blocked using a blocking reagent. Then a detection antibody is added 
specific for the antigen which is detected once the secondary antibody is given. The 
secondary antibody in this case, is covalently linked to an enzyme like peroxidase which 
can metabolize colourless substrates into colour. Washing steps were performed in-
between to remove non-specific antigen or antibody binding complexes. The detection of 
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present antigen is performed when the addition of the enzyme substrate is added causing 
a colour change (optical density) which can be detected by spectrophometry.    
 Serum concentrations for whole Ig and Ig isotypes were performed by ELISA using 
the capture antibody goat anti mouse IgG and secondary antibodies HRP conjugated 
against IgG, IgG1, IgG2a, IgG2b and IgM (Sigma). The optical density readings were 
normalized against the isotype controls from sigma.  
  Anti-histone and anti-dsDNA antibodies in serum were measured (as described in 
Zhu et al., 2008). 
 
2.13 Experimental Autoimmune Encephalomyelitis  
 
 Experimental autoimmune encephalomyelitis (EAE) was induced into the mice 
using a myelin oligodendrocyte glycoprotein (MOG)35–55/CFA emulsion kit (EK-0111; 
Hooke Laboratories) according to the manufacturer’s protocol subcutaneously. The mice 
were induced with 100μl Pertussis Toxin and re-administered 24 hours later. Recordings 
for the progression of the disease were calculated by clinical scoring relating to the 
severity of the disease as shown in Table 3. After thirty days from the initial induction, the 
mice were sacrificed and CNS tissues were taken and immediately fixed with 10% 
formalin in PBS and embedded in paraffin. Haematoxylin and eosin staining was 
performed on those paraffin sections.  
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Stage of disease Signs 
0   Mice appear normal 
1   Limp tail/hind limb weakness 
2   Limp tail and hind limb weakness 
3   Partial hind limb paralysis 
4   Complete hind limb paralysis 
5   Death, moribund state 
Table 3: EAE Clinical Scoring and Severity of Disease  
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Chapter 3: Results 
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3.1 Establish K2/3 knockout model 
3.1.1 Genotyping of CD2-specific EGR-2 knockout models  
 
 The model carries CD2-Cre transgene and floxed EGR-2 at exon 2 under C57/BL 
background as described previously (Zhu et al., 2008). In order to use this model to create 
K2/3 in lymphocytes, confirmation of the Cre gene and Egr-2–loxp locus by genomic PCR 
analysis was performed (Figure. 1). The data showed that the parental mice of CD2-
specific Egr-2-/- had both Cre and floxed EGR-2 genes (Figure. 1).   
 
                                   
Figure 1: Genotyping of CD2+ cell-specific EGR-2-/- mice. Cre primers were used to detect 
the presence of the iCre transgene to yield a 150 bp and the LoxP primers to yield 210bp 
products.  The genotype from mouse in lane 1 represents EGR-2f/f as shown by the upper 
210bp band and cre transgenic negative. The mouse in lane 2 represents EGR-2f/f CD2-
Cre positive. Lane 3 genotype represents EGR-2f/- CD2-Cre. Finally, the genotype of the 
mouse from lane 4 is CD2-Cre transgenic.  
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3.1.2 Genotype of EGR-3 KO model 
 
 Unlike conventional EGR-2 KO mice, the EGR-3KO is principally normal in 
phenotypes of major organs with a degree of defect in the central nervous system 
including ataxia, scoliosis, ptosis and tremors (Tourtellotte and Milbrandt., 1998). 
Previous studies also found a defect of thymocyte development in EGR-3 KO mice 
showing thymic atrophy due to a partial block at DN3 which reduces proliferation of 
subsequent DN4 (Carter et al., 2007)  and reduced susceptibility to anergy induction 
(Safford et al., 2005). However, the function of effector lymphocytes in the periphery is 
normal. We obtained EGR-3 KO under C57BL background mice from St Louis, Missouri 
(Tourtellotte and Milbrandt., 1998). Genotyping of EGR-3KO mice was performed by 
genomic tail DNA PCR analyses. PCR primers were designed to detect the presence of the 
neo allele that confirmed EGR-3 inactivation of the WT allele. The data showed that the 
parental EGR-3KO had the neomycin insertion or were WT. Selection of the neo allele was 
used for breeding for generating the K2/3 model (Figure. 2) 
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Figure 2: Genotyping EGR-3KO using PCR. Neo specific primers were used to detect the 
Neo cassette insertion that deleted the total zinc finger domain of EGR-3.  This yielded a 
735 bp PCR product. (Lane 3) The WT allele yielded a 350 bp product (Lane 2).  The 
presence of one neo allele and one WT allele gave both the 735 bp and 350 bp PCR 
products (Lane 1).  The Neo positive mice were used for subsequent breeding of K2/3 
mice (Lane 3). 
 
3.1.3 Creation of the EGR-2 and EGR-3 double knockout mouse model 
 
 As already described earlier, EGR-2 and EGR-3 family members share similar 
structure and function. Single EGR-2 and EGR-3 knockout models have shown no 
significant defect in lymphocyte function. So to explore further EGR-2 and EGR-3’s gene 
function we generated a double knockout mouse model.   
 The EGR-2cKO-/- male as previously described was bred together with the female 
EGR-3KO-/- mouse that produced the F1 generation (Figure. 3, A). Each generation of mice 
that followed, were tail genotyped by PCR. The F1 generation produced, had the 
phenotype of EGR-2+/-/EGR-3+/- (Figure. 3, A). The F1 littermates were bred with each 
other and produced the F2 generation that had the phenotype EGR-2+/-/EGR-3+/+, EGR-2-/-
/EGR-3-/-, EGR-2+/+/EGR-3+/+ and EGR-2+/+/EGR-3+/- (Figure. 3, A). Twenty five per-cent of 
the litter were EGR-2 and EGR-3 homozygous or wild type and fifty per-cent of the litter 
were EGR-2 and EGR-3 heterozygous. 
 From the F2 generation, EGR-3-/- or EGR-3+/- and EGR-2-/- or EGR-2+/- were selected 
for breeding pairs from the double knockout mice. The F3 generation of mice had the 
phenotype, EGR-2-/- and EGR-3-/- homozygous, EGR-2-/- EGR-3+/- and EGR-2+/- EGR-3-/- 
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heterozygote’s (Figure. 3, A). One third of the litter were EGR-2 and EGR-3 homozygous 
and two thirds were EGR-2 or EGR-3 homozygous and heterozygous for either gene.  
 From the F3 generation, more EGR-2 and EGR-3 homozygotes could be selected as 
breeding pairs for the double knockouts and were used for breeding for the F4 
generation. The final breeding pair to generate the double knockout generation was EGR-
2-/- EGR-3-/- (Figure. 3, A). We confirmed the genotype of the EGR-2-/- EGR-3-/- mice by 
genomic tail PCR analysis. The primers used to test for Cre, LoxP and Neo are described as 
before in 3.1.1 and 3.1.2 (Figure. 3, B). 
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Figure 3: Generating the EGR-2-/- EGR-3-/- double knockout final breed. (A) Schematic 
overview of how we created the EGR-2-/- EGR-3-/- double knockout breed. Parental EGR-2-
/- and EGR-3-/- were used for the generation of the F1 hybrid EGR-2+/- EGR-3+/-. These mice 
were then bred together to produce the F2 hybrid where the EGR-2+/- EGR-3+/+, EGR-2-/- 
EGR-3-/- and EGR-2+/+ EGR-3+/- were used as breeding pairs that generated the F3 hybrid. 
From the F3 hybrid the EGR-2-/- EGR-3-/- were bred to generate the final breeding pair F4. 
(B) Genotyping was performed to check the presence of Cre, LoxP f/f and Neo in the tail 
DNA. 
  
 This thesis focusses on the K2/3 mouse model; however we also generated an 
EGR-2Tg mouse model to study the overexpression of EGR-2 in CD2 specific cells (Li et al., 
2011). Genotyping was performed on tail DNA by PCR analyses to yield a 350bp PCR 
product (data not shown).  
 
 
 
B 
Neo allele: 735bp  
LoxP allele: 210bp  
Cre allele: 150bp  
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3.1.4 Confirmation of the defect in EGR-2/EGR-3 expression in K2/3 mice at mRNA and 
protein level  
 
 As previously shown, we confirmed genomic deletion of EGR-2 and EGR-3 (Figure. 
3, B). We further validated this at mRNA and protein expression levels. Both CD4 and B 
cells from WT and K2/3 mice were either unstimulated or stimulated for 6 hours with 
anti-CD3 and anti-CD28 for T cells or IgM for B cells. EGR-2 and EGR-3 have been shown 
to be expressed after antigenic stimulation (Anderson et al., 2006), for both the mRNA 
and protein expression levels, unstimulated samples were used as a negative control 
(Figure. 4, A, B). The WT sample was used as a positive control to show the endogenous 
EGR-2 and EGR-3 mRNA expression in both the unstimulated and stimulated conditions in 
T and B cells (Figure. 4, A). For the mRNA expression levels of EGR-2 and EGR-3 , WT and 
K2/3 CD4 and B cells were stimulated for 6 hours with indicated antigen and RT-PCR was 
performed relative to β-actin expression (Figure. 4,A). The results showed that from the 
unstimulated results, WT and K2/3 CD4 and B cells showed no EGR-2 and EGR-3 mRNA 
expression (Figure. 4, A). From the stimulated results, WT CD4 and B cells showed high 
EGR-2 and EGR-3 mRNA expression (Figure. 4, A). Whereas K2/3 CD4 and B cells, showed 
no EGR-2 and EGR-3 mRNA expression in stimulated cells, which confirms that there is 
complete excision of EGR-2 and EGR-3 (Figure. 4, A).  
 Complete excision of EGR-2 and EGR-3 in the CD2 expressing cells had been 
confirmed by RT-PCR (Figure. 4, A), we also wanted to further confirm this at protein level 
by immunoblotting. Immunoblotting (referred to as Western Blotting) is a technique used 
to detect protein in a given sample. In this case we used the same cell extracts from WT 
and K2/3 CD4 and B cells and stimulation conditions as described for RT-PCR. We showed 
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here that for both WT and K2/3 unstimulated CD4 and B cells, there was no detectable 
EGR-2 or EGR-3 protein expression consistent in our confirmation of complete excision of 
EGR-2 and EGR-3 in CD2 expressing cells from K2/3 mice (Figure. 4, B). More importantly 
we showed that after stimulation, there is no EGR-2 or EGR-3 protein expression in K2/3 
mice, whereas our positive control, WT showed high protein expression in both CD4 and 
B cells (Figure. 4, B). In conclusion, we demonstrated here that the K2/3 mice showed 
complete excision of EGR-2 and EGR-3 at mRNA and protein expression levels.   
 
 
 
 
Figure 4: Defective expression of EGR-2 and EGR-3 confirmed by RT-PCR and 
immunoblotting. Splenic CD4 and B cells from WT and K2/3 mice were either 
unstimulated or stimulated with anti-CD3 and anti-CD28 for CD4 T cells or anti-IgM for B 
cells for six hours. (A) mRNA expression levels of EGR-2 and EGR-3 were confirmed by RT-
PCR and (B) protein expression levels of EGR-2 and EGR-3 were confirmed by 
immunoblotting. The RT-PCR data was represented relative to β-actin expression. The 
data presented here was representative from two experiments (The data is taken from Li 
et al., 2012, in which I am one of the co-authors).  
 
A B 
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3.2 Development of autoimmune disease in K2/3 mouse model  
 
 We have already shown that in EGR-2cKO mice they developed lupus-like 
autoimmune disease with a high infiltration of mononuclear cells in the liver, kidney and 
spleen (Zhu et al., 2008). The phenotype of the accumulating cells expressed CD25, CD44 
and CD69 (Zhu et al., 2008). EGR-2cKO histology sections show high infiltration of cells in 
the liver and kidney, whilst more white pulp in the spleens of 15 month old mice (Zhu et 
al., 2008). We therefore wanted to investigate the phenotype in EGR-2 and EGR-3 
deficient mice. From observing the mice, when the K2/3 litter reached 2-3 months of age, 
they began to become less motile and reduced their food intake. The mice after 8 months 
became increasingly less motile and some were moribund. This suggested that possibly 
EGR-2 and EGR-3 regulated the development of autoimmune disease. Therefore we 
measured cytokine expression levels and self-reactive antibodies from WT, K2/3, Tg, K2 
(EGR-2cKO) and K3 (EGR-3KO) mice over time for 30 weeks. We observed that K2/3 mice 
showed increasing levels of IFN-γ and self-reactive antibodies as early as 5 weeks after 
birth whereas WT, Tg and K3 mice showed undetectable levels (Figure. 5, A).  
Interestingly we showed that K2 mice displayed IFN-γ expression and self-reactive 
antibodies between 20-25 weeks of age which confirms our group’s previous result that 
EGR-2cKO mice develop autoimmune disease in later life (Zhu et al., 2008) (Figure. 5, A). 
When there is a deficiency of both EGR-2 and EGR-3, the onset of autoimmune disease is 
much earlier in life which we proposed is due to compensatory role that EGR-3 plays in 
the absence of EGR-2. Our positive control in this experiment was the Tg mice who 
showed no detectable signs of autoimmune disease explaining why these transcription 
factors are essential (Figure. 5, A).  
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  We also wanted to investigate the Ig serum levels from our K2/3 mice as our 
group previously found high serum IgG in EGR-2cKO mice (Zhu et al., 2008). We showed 
here that there are also high serum IgG concentrations in K2/3 mice from ELISA results, 
particularly IgG2 which is important for the Th1 mediated inflammatory response (Zhu et 
al., 2008) (Figure. 5, B). However, IgG1 was low, which is similar to what our group 
previously published (Zhu et al., 2008) as it mediates a Th2 response, not associated with 
inflammation (Figure. 5, B).  
 To study the development of autoimmune disease in K2/3 mice, we measured 
self-reactive antibodies, a hallmark of autoimmune disease. Urine protein levels and anti-
dsDNA in K2/3 and WT mice were also measured. Urine protein levels were measured 
because the kidney is one of the major organs that show tissue damage and inflammation 
in SLE patients. We not only measured urine protein levels, anti-dsDNA and histone were 
also examined at two time points, 4 weeks and 8 weeks; this is because we have already 
shown from Figure. 5, A that the mice develop autoimmune disease early so we chose 
those time frames. dsDNA refers to the antigen specific autoantibodies and histone is the 
DNA and protein interactions that generate the autoantigens, both are believed to be 
important for detecting autoimmunity. We found urine protein levels increased fourfold 
between 4-8 weeks in K2/3 mice compared with WT mice (Figure. 5, C). The self-reactive 
antibody levels were fivefold higher in 4-8 week K2/3 mice compared with WT mice 
(Figure. 5, C). To further analyse this, we also did immunohistochemistry and took kidney 
sections and fluorescently labelled them with Texas Red Ig to show the IgG deposits. We 
showed here that there were large deposits of IgG in the K2/3 kidney section compared 
to WT (Figure. 5, D). These results confirmed high levels of autoreactive antibodies and 
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IgG deposits in the glomeruli which indicated that the K2/3 mice had developed systemic 
autoimmune disease.  
 We wanted to observe pro-inflammatory cytokines in CD4 T cells isolated from 
WT, K2/3 and Tg 4 week old mice and compare un-stimulated or stimulated conditions 
with anti-CD3 and anti-CD28 (Figure. 5, E). mRNA expression levels for IL-2, IL-17A, IL-21, 
IL-4, GM-CSF and IFN-γ were measured by RT-PCR (Figure. 5, E). We showed that in 
unstimulated conditions, K2/3 mice had increased production of pro-inflammatory 
cytokines IL-17A, IL-21, IL-4, GM-CSF and IFN-γ compared with WT and Tg (Figure. 5, E). 
Furthermore, when the cells were stimulated, K2/3 mice showed a threefold increase in 
these cytokines, compared with Tg mice (Figure. 5, E). Interestingly the K2/3 mice showed 
impaired IL-2 mRNA expression once stimulated, compared to Tg which show a fourfold 
increase in comparison (Figure. 5, E). These results showed that EGR-2 and EGR-3 play an 
important role in regulating autoimmune disease and inflammation.  
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Figure 5: EGR-2 and EGR-3 deficient mice develop severe systemic autoimmune disease 
and display increased inflammatory cytokines. (A) Measurement of onset of 
autoimmune disease by serum IFN-γ and self-reactive antibodies comparing WT, K2/3, Tg, 
K2 and K3.(B) ELISA serum levels of Ig from WT and K2/3 3 month old mice. (C) 
Measurement of self-reactive antibodies and protein in urine from 3 month old WT and 
K2/3 mice (D) Texas Red anti-mouse Ig labelled for IgG deposits in the glomeruli from 3 
month old K2/3 mice. (E) WT, K2/3 and Tg CD4 T cells after stimulation with anti-CD3 and 
anti-CD28 for 16 hours were measured for cytokine levels in mRNA expression by RT-PCR. 
The data from [A] was representative of 4 mice from two experiments. The data from [B], 
and [C] were the mean standard deviation from four mice. [D] was representative of four 
mice and [E] was measured relative to β-actin from three experiments. ND= Not detected 
(the figures are taken from Li et al., 2012, in which I am one of the co-authors). 
 
3.3 Susceptibility of EAE autoimmune disease in EGR-2cKO mice 
  
 EGR-2 and EGR-3 deficient mice developed autoimmune disease where a 
deficiency in both transcription factors resulted in an earlier onset of autoimmunity 
compared with EGR-2cKO (Figure. 5). EGR-2cKO mice were used to see if we can induce 
autoimmune disease. There are many autoimmune disease models including EAE, 
adjuvant arthritis and systemic lupus erythematosus (Farine., 1997). We decided to use 
the EAE mouse model because you can observe early stages of the disease and monitor 
the progression using clinical scoring (Farine., 1997).  To study the susceptibility of 
autoimmune disease using the EAE mouse model in 10-12 week WT and EGR-2cKO mice, 
immunization with MOG35-55 peptides was used. These peptides are autoantigens derived 
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from CNS myelin and they are involved in inducing a high T and B cell response which 
manifests into demyelination and plaque formation giving rise to tissue damage and an 
inflammation immunopathology. The mice were induced with pertussis toxin and 
monitored up to 30 days and clinical symptoms from clinical scoring were recorded. The 
early signs of development of the disease were similar from both WT and EGR-2cKO at 
day 9 (Figure.  6, A). However, the progression of the disease was more severe in the 
EGR-2cKO mice as shown by a higher clinical score and symptoms compared with WT 
(Figure. 6, A). The pathology of EAE disease was examined by H and E staining on WT and 
EGR-2cKO from CNS tissues with clinical scoring of I. The staining results revealed that 
there was a massive infiltration of mononuclear cells situated around the spinal cord in 
the EGR-2cKO cells compared with WT (Figure. 6, B). The infiltration of cells found in the 
EGR-2cKO CNS tissues confirmed the severity of clinical symptoms and scores we 
obtained (Figure. 6, A, B). To examine the phenotype of the infiltrating cells found in the 
spinal cord, mononuclear cells were isolated for CD4+ cells and double stained with IL-17 
and IFN-γ, cytokines expressed in autoimmune disease. The results showed a fivefold 
increase in expression of IL-17 from CD4+ cells in EGR-2cKO compared with WT (Figure. 6, 
C). The results indicated that the mice were more susceptible to the development of 
autoimmune disease when EGR-2 is deleted.   
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Figure 6: EGR-2cKO has increased susceptibility to develop EAE disease. (A) Data 
showing clinical scoring of stage and symptoms after immunisation with MOG35-55 from 
five WT and EGR-2cKO mice with as shown in Materials and Methods. (B) H and E staining 
from CNS tissues with a clinical scoring of I at 30 days post immunization at x10 
modification. (C) CNS tissues from five immunized mice were isolated for mononuclear 
cells and stained with CD4, IFN-γ and IL-17A and gated on CD4+ cells. All the data 
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presented were representative of three experiments on five mice in each (the figures are 
taken from Miao et al., 2013, in which I am one of the co-authors).  
 
3.4  Role of EGR-2 and -3 in T cell receptor signalling  
3.4.1 EGR-2 and -3 double deficiency results in impaired proliferative responses of T 
cells to antigen receptor stimulation 
 
 In Figure. 5, E we showed defective IL-2 mRNA expression in K2/3 mice. Similarly, 
SLE patients showed impaired in-vitro stimulation after antigenic stimulation (Gottlieb et 
al., 1979). In rheumatoid arthritis patients, ex-vivo analysis also found a defect in the 
ability of the T cells to proliferate (Wagner et al., 2004). To study the role that these 
transcription factors play in regulating T cell proliferation after antigen receptor 
stimulation, T and B cells isolated from splenocytes of K2, K3, WT, Tg and K2/3 mice were 
stimulated in-vitro with anti-CD3 and anti-CD28 for T cells and IgM for B cells aiming to 
mimic antigen stimulation.  The proliferation was measured by BrdU or [3H]thymidine  
incorporation assays. BrdU is a synthetic thymidine that gets actively incorporated into 
newly synthesised genomic DNA during S phase and it can be detected by BrdU specific 
antibody conjugated with a fluorescent marker and visualised using Flow Cytometry.  The 
other technique used to measure cellular proliferation was [3H]thymidine. This technique 
uses radioactive nucleoside [3H]thymidine that gets actively incorporated into newly 
synthesised DNA during DNA synthesis. The difference between BrdU and [3H]thymidine 
is that BrdU labelling is specific and can identify what cells are dividing compared to 
undivided, however, [3H]thymidine cannot distinguish specific cells from a population 
that are dividing. The mice from K2, K3, K2/3 and Tg CD4 T cells were stimulated for three 
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days with anti-CD3 and anti-CD28 for T cells. K2 and K3 cells showed similar proliferation 
compared with WT, indicating that single knockout of these transcription factors did not 
have an effect on T cell proliferation (Figure. 7, A). Significantly K2/3 cells showed a 
defect in cell proliferation compared with WT (Figure. 7, A). Similar results were shown by 
3H-TdR incorporation (Figure. 7, B). In contrast, EGR-2 expressing CD4 T cells from Tg 
showed a fourfold increase in cell proliferation following antigenic stimulation in both 
BrdU and 3H-Thymidine incorporation assays (Figure. 7). This demonstrates that EGR-2 
and EGR-3 are important for activating T cell proliferation after mitogenic stimulation. 
The absence of both EGR-2 and EGR-3 causes a severe defect in the ability of cells to 
proliferate after mitogenic stimulation.  
 
 
 
                                                                                                                                                     
 
 
 
 
 
Figure 7: EGR-2 and -3 plays a role in regulating T cell receptor signalling. (A) 
Proliferation results from BrdU incorporation into naïve CD4 T cells from WT, K2, K3, Tg 
and K2/3 after stimulation with anti-CD3 and anti-CD28 for three days. (B) CD4 and B cell 
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proliferation results measured by 3H-TdR incorporation after anti-CD3 and anti-CD28 
stimulation for three days for T cells and IgM and LPS for B cells.  Data represented three 
independent experiments (figure is taken from Li et al., 2012, in which I am a co-author). 
 
3.4.2 The impaired proliferation in EGR-2 and -3 deficiencies is due to defective AP-1 
activation in both T and B cells  
  
 As previously shown EGR-2 and EGR-3 deficient mice have the impaired ability to 
proliferate after antigen receptor stimulation (Figure. 7, A) and play important roles in 
the development of B and T cells (Li et al., 2011). EGR-2 and EGR-3 have been shown to 
be targets for NFAT which mediates calcineurin pathway in TCR signalling and also 
induces FasL expression in T cells (Rengarajan et al., 2000). To identify the role that both 
of these transcription factors play in TCR signalling we explored which of the signalling 
pathways were affected. TCR signalling is a series of multiple steps starting with T cell and 
antigen presenting cell engagement, followed by CD3 phosphorylation and further 
downstream signalling to activate MAP kinase proteins such as ERK, Fos and AP-1 
(Rengarajan et al., 2000). Data has shown that AP-1, NFAT and NF-κB are activated once 
TCR engagement has been initialised which can then go on to induce IL-2; therefore we 
wanted to explore these signalling proteins (Kim et al., 2009). We observed ERK, NFκB, 
NFAT and AP-1 signalling components for TCR signalling. Naïve T and resting B cells from 
WT and K2/3 knockout cells were either stimulated or un-stimulated with anti-CD3 and 
anti-CD28 or IgM (Figure. 8, A). Cytoplasmic extracts were used to measure ERK 
phosphorylation and other proteins such as AP-1, NFAT and NFκB are present in the 
nucleus so nuclear extracts were used for those. To check if there was an association of 
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EGR-2 and EGR-3 with these proteins, EMSA was performed on stimulated and un-
stimulated T and B cells. EMSA is able to detect DNA and protein complexes from nuclear 
extracts to a consensus probes for a particular binding sequence. The EMSA technique is 
based on the fact that free DNA and probe will migrate faster through the gel, whereas 
protein-DNA complexes will migrate slower. The addition of another antibody can cause a 
supershift which can reveal a further protein involved in the complex that will migrate 
even slower through causing a supershift.  
 Erk detection was used as a control to show cellular expression before T cell 
activation in WT and K2/3 stimulated and un-stimulated T and B cells (Figure. 8, A, row 2). 
Consensus probes for AP-1, NFκB and NFAT were used in the binding reaction with 
nuclear extracts from WT or K2/3 T and B cells stimulated or un-stimulated.  The 
presence of proteins pERK, NFκB and NFAT and AP-1 were shown to be only produced 
after antigenic stimulation, whereas the negative control using un-stimulated WT or K2/3 
cells showed no expression of these proteins (Figure. 8, A, lane 1, 2, 5 and 6).  The results 
indicated that MAP Kinases (phosphorylation of Erk), NFκB and NFAT were not defected 
in B and T cells in K2/3 as compared with WT (Figure. 8, A, row 2, 4 and 5). However, AP-1 
activation was impaired in K2/3 samples compared to WT (Figure. 8, A). Interestingly, 
despite reduced AP1 binding in EMSA, the results showed a lower alternative binding 
complex in B and T cells from K2/3 mice compared with WT (Figure. 8, A and B). In order 
to compare the levels of differences, the intensity of AP1 binding complexes detected in 
EMSA was measured by the phosphorimager. The relative intensity of AP1 binding 
complexes in CD4 T cells from WT was threefold higher than that of EGR-2 and EGR-3 
deficient CD4 T cells after normalization to the internal control SP1 (Figure. 8, B ). Thus, 
the activity of classic AP-1 was impaired in CD4 T cells from K2/3 mice, demonstrating 
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EGR-2 and EGR-3 are important for the induction and/or maintenance of AP-1 activation 
in response to antigen receptor stimulation.  
 To further confirm AP1 binding anti-cFos and anti-JunB antibodies were used to 
do super-shift. The anti-cFos antibody shifted up in WT CD4 cells while in K2/3 CD4 cells; 
there was no supershift (Figure. 8, C). Interestingly the EMSA results (Figure. 8, A and C) 
showed that typical AP-1 activation was impaired in the K2/3 samples however, the 
addition of anti-JunB antibody caused a supershift in the EMSA gel revealing that this 
protein was important in the AP-1 binding complex in K2/3 compared with WT that 
showed no change (Figure. 8, C). AP-1 activation is composed of many different proteins 
that dimerise with each other to bind to DNA binding sequences that can activate other 
genes. Here we showed that part of the AP-1 defect in EGR-2 and EGR-3 deficient mice 
did involve the protein JunB. However, there are lots of other proteins in the AP-1 family. 
So further analysis using the AP-1 DNA binding probe against anti-cFos in WT or K2/3 
revealed that c-Fos appeared to not be important for the deficiency of AP-1 activation 
seen in K2/3 compared with WT (Figure. 8, C). This indicated a possible link between EGR-
2 and EGR-3 binding with JunB for AP-1 activation.  
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Figure 8: EGR-2 and -3 KO show reduced AP-1 activation in lymphocytes. (A) Naive CD4 
and resting B cells were stimulated with anti-CD3 and anti-CD28 for T cells or anti-IgM for 
B cells. Cytoplasmic extracts was measured for Erk phosphorylation. Nuclear extracts 
were subjected to EMSA for NFκB, NFAT and AP- 1 with the consensus probe and the 
arrows are indicative of other complexes that are also bound to the AP-1 probe. (B) 
Phosphorimager results to quantify the AP-1 intensity bands from (A) and normalised by 
using SP1 internal control. (C) EMSA results from anti-CD3 and anti-CD28 stimulated CD4 
T cells, extraction of nuclear content with AP-1 DNA probe against JunB and c-Fos. Data 
from [A] and [B] are representative of three independent experiments, whereas [C] is 
representative of two experiments (the data represented is taken from Li et al., 2012, in 
which I am one of the co-authors). 
A 
B C 
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3.5 The role of Batf in the regulation of AP-1 signalling 
3.5.1 Batf is part of the lower AP-1 binding complex  
  
 The impaired AP-1 activation in K2/3 deficient B and T cells indicated that EGR-2 
and EGR-3 may be involved directly in the regulation of AP-1 activation. The AP-1 
complex is composed of many different proteins that form homo or hetero-dimers with 
each other to bind to AP-1 consensus DNA. Batf is a small nuclear protein that is 
expressed in hematopoietic organs such as spleen, thymus and lymph nodes. Batf is a 125 
amino acid nuclear protein and is a member of the AP1 family (Williams et al., 2001). 
However, it does not contain a trans-activation domain (Williams et al., 2001). Batf forms 
heterodimers with Jun proteins which bind to consensus AP-1 DNA. However, the Batf-
AP1 complexes do not have AP1 function as they cannot transactivate the target genes. 
Also forced expression of Batf in fibroblast cells blocks cellular transformation of the cells 
and increases the longevity of the cells in culture (Williams et al., 2001). This was 
confirmed by Echlin et al., 2000 group who isolated portions of the Batf protein and fused 
with the DNA binding domain of the yeast GAL4 promoter. They demonstrated that Batf 
could not trans-activate the CAT reporter plasmid from the different portions of the Batf 
protein. Batf can however, regulate Th17 differentiation, by binding with the IL-17 
promoter (Schraml et al., 2009). EMSA results from whole Th17 cell extracts subjected to 
the AP-1 DNA probe, revealed two complexes in the Batf positive Th17 cell extracts 
(Schraml et al., 2009). Only the upper complex was found in Batf knockout Th17 cell 
extracts. To show Batf directly interacts with AP-1, supershift analyses was performed on 
CD2-N-Flag-Batf-transgenic Th17 cell extracts using the anti-flag antibody (against Batf) 
which supershifted the lower complex, revealing the lower complex that binds to the AP-
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1 DNA probe from Th17 cell extracts contains Batf (Schraml et al., 2009). Batf is also 
essential for thymic NKT cell development and a deficiency in Batf leads to inadequate 
differentiation of Th17 T cells (Logan et al., 2012).   
 The EMSA results shown in Figure. 8, A and C revealed a lower complex from AP-1 
binding in K2/3 T and B cells. As already shown from Schraml et al., 2009 data, Batf was 
shown to be in the lower complex from the AP-1 binding probe in Th17 cell extracts. To 
investigate whether Batf may also be involved in the alternative lower complex seen in 
the K2/3 T and B cell EMSA results (Figure. 8, A), EGR-2, Batf or double transfected 
HEK293 cells were used to perform EMSA to examine AP-1 DNA binding activity (Figure.  
9). An AP-1 DNA probe was labelled with 32P and used for binding assay. Figure. 9, lane 1 
represented un-transfected negative control cells, showing no AP-1 binding when neither 
EGR-2 nor Batf were present. Figure. 9, lanes 2 and 3 represented positive controls from 
either EGR-2 transfected or Batf transfected HEK293 cells showing that EGR-2 directly 
bound with AP-1 (lane 2) or Batf directly bound with AP-1 forming an alternative lower 
complex (lane 3). Figure. 9, lane 4 showed the HEK293 cells co-transfected with EGR-2 
and Batf blocked the binding to the consensus AP-1 probe. To test which complex 
contained Batf, supershift analysis using an anti-myc antibody (for Batf) in HEK293 cells 
transfected with Batf was used (Figure. 9, lane 5). The addition of an anti-Batf antibody 
supershifted the lower AP-1 binding complex. To test whether another molecule, JunB 
was important in the AP-1 complex from EGR-2 transfected HEK293 cells, anti-JunB 
antibody was used for supershift analyses (Figure. 9, lane 6). The results showed that the 
addition of anti-JunB antibody supershifted the upper AP-1 complex (Figure. 9).  
  The results revealed EGR-2 was part of the AP-1 binding complex, whilst Batf 
blocked the conventional AP-1 complex; however, it was part of the alternative lower AP-
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1 consensus binding complex. Co-transfection of Batf and EGR-2 blocked the conventional 
AP-1 consensus DNA binding.    
 
 
 
Figure 9: Batf is part of the lower complex in AP-1. HEK293 cells were transfected with 
Flag-tagged EGR-2 or Flag-tagged EGR-2 plus Myc-tagged Batf. The lysates were 
immunoprecipitated with anti-Flag-tag or anti-Myc-tagged antibodies. EMSA supershift 
analysis was performed with the AP-1 DNA probe. The data is representative of three 
experiments (Li et al., 2012).  
 
3.5.2 Direct interaction between EGR-2 and Batf  
 
 To examine whether EGR-2 can interact with Batf, HEK293 cells were co-
transfected with flag tagged EGR-2 plus myc tagged Batf (Figure. 10). Flag or myc tagging 
allows detection of tagged protein with antibodies specific to the tag. The expression of 
both proteins was confirmed by immunoblotting with antibodies specifically to Flag or 
Myc, respectively (Figure. 10). To examine the interaction, the total protein lysates from 
transfected cells were immunoprecipitated with antibody either against Flag (for Flag 
    1      2       3     4      5      6 
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EGR-2 cells) or Myc (for Myc Batf cells), this allowed the pulling out of a tagged molecule 
and the molecules associated with it. The immunoprecipitates were separated and 
transferred onto a nitrocellulose membrane with antibodies for anti-EGR-2 or anti-Myc 
for anti-Flag added to the precipitates, this allowed you to see whether EGR-2 and Batf 
presented in each other’s precipitates. Indeed, EGR-2 was detected in the precipitates of 
myc-tagged Batf while Batf was detected in the EGR-2 precipitates (Figure. 10). To further 
confirm the interaction, a reciprocal co-immunoprecipitation test was carried out on the 
same lysate. The results were consistent (Figure. 10). The immunoblotting with EGR-2 on 
total lysate from immunoprecipitated Flag tagged EGR-2 cells was used as a control to 
show total EGR-2. The results showed that EGR-2 did directly bind with Batf (Figure. 10). 
 
 
 
 
 
 
 
Figure 10: Direct interaction of EGR-2 with Batf. The same HEK293 cells transfected as 
indicated (figure. 9) were used to perform Western Blot with anti-Myc and anti-EGR-2 for 
the anti-Flag precipitated samples or anti-Flag anti-Batf for anti-Myc precipitated 
samples. The data is representative of two experiments (Li et al., 2012). 
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3.5.3 siRNA knockdown of Batf, restores AP-1 consensus DNA binding in K2/3 T cells 
 
 The results so far have shown that when EGR-2 binds with Batf, AP-1 activation is 
inhibited (Figure. 9). To confirm this, AP-1 activation should be restored if Batf is 
removed, thus knockdown of Batf was created. Knockdown of Batf was achieved by the 
addition of short interfering oligonucleotides (siRNA) against Batf, EGR-2 and EGR-3 
mRNA. By adding these siRNA’s against specific sequences of mRNA, those target genes 
will have reduced expression. As a negative control, siRNA not specific for any mRNA 
(con) was also transfected into the cells, to serve as a basal level for comparison with 
targeted siRNA. To check whether mRNA expression is reduced, RT-PCR was performed. 
CD4 T and CD19 B cells were transfected with siRNA (control) or siRNA specific for Batf 
from WT or K2/3 T cells. RT-PCR analysis was performed on Batf expression (Figure. 11, 
A). The cells were stimulated for 16 hours with anti-CD3 and anti-CD28 for T cells or IgM 
for B cells and un-stimulated cells served as a control. From the un-stimulated B and T cell 
RT-PCR results, in both WT and K2/3 cells, Batf expression was low because Batf will only 
be expressed after T cell receptor activation (Figure. 11, A). From the stimulated results, 
WT and K2/3 T and B cells transfected with siRNA (con) showed high expression of Batf 
(Figure. 11, A). The WT and K2/3 cells transfected with siRNA specific for Batf showed 
efficient knockdown whereby Batf mRNA expression was reduced (Figure. 11, A). 
 Knockdown of Batf was proved by reduced Batf mRNA expression levels, to 
further confirm reduced expression levels, Western Blot was performed (Figure. 11, B). 
Protein expression levels confirmed the RT-PCR results. WT and K2/3 T and B cells 
transfected with siRNA (con) and blotted with anti-Batf antibody showed normal Batf 
protein expression. However, cells transfected with siRNA specific for Batf, 
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immunoblotted with anti-Batf antibody showed very low protein expression (Figure. 11, 
B). Immunoblotting with β-actin was used as a control to show basal protein expression 
levels in WT and K2/3 transfected cells (Figure. 11, B). The RT-PCR and Western Blot 
results showed that siRNA knockdown of Batf in WT and K2/3 cells was efficient (Figure. 
11).  
 Previously Batf has been shown to inhibit AP-1 activation and slow down cell 
growth (Lio et al., 2011).  This group found that M1 cells (Mouse myeloid leukemia cell 
line) transfected with Batf-RNAi and monitored for cell growth for 7 days in the absence 
or presence of LIF/IL-6 cytokines grew slower with fewer cells compared with WT cells 
(Lio et al., 2011).  As Batf inhibits AP-1 activation, knockdown of Batf should restore 
lymphocyte proliferation in K2/3 cells, thus 3H-thymidine incorporation and IL-2 
expression was explored in those knockdown cells. WT and K2/3 CD4 and CD19 cells were 
transfected with siRNA as already described and stimulated with anti-CD3 and anti-CD28 
for T cells and IgM for B cells with the addition of 3H-thymidine for 48 hours. The negative 
control used was un-stimulated cells, where both WT and K2/3 T and B cells showed 
reduced cell proliferation and low IL-2 expression as expected (Figure. 11, C). In contrast, 
CD4 and B cells from WT transfected with control siRNA showed high levels of 
proliferation, however, the same transfected cells from K2/3 showed low proliferation 
levels and IL-2 expression, due to impaired AP-1 activation (Figure. 11, C). Also CD4 and B 
cells stimulated from WT cells transfected with siRNA for Batf showed similar 
proliferation levels compared with control siRNA. Interestingly from K2/3 results, 
proliferation and IL-2 expression was rescued after knockdown of Batf, proving that EGR-
2 binding with Batf does have a functional effect in lymphocytes (Figure. 11, C). As Batf 
represses AP-1 activation, to observe whether knockdown of Batf can restore AP-1 
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activation, the same samples as described were used for EMSA. The results from WT CD4 
and B cells transfected with control or Batf siRNA, showed normal AP-1 activation (Figure. 
11, C). On the other hand, K2/3 T and B cells transfected with control siRNA showed 
reduced AP-1 activation as Batf inhibits AP-1 activation; however formation of a lower 
complex was present. K2/3 cells transfected with siRNA for Batf revealed the formation of 
two complexes, showing that the lower complex contains Batf (Figure. 11, D).  
 
 
 
 
B A 
C D 
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Figure 11: Batf is knocked down in EGR-2 and -3 deficient cells restored AP-1 activation. 
(A) and (B) WT and K2/3 CD4 and CD19 cells were transfected with control siRNA (con) or 
Batf specific siRNA (Batf) to show knockdown of Batf. The cells were stimulated with 
either anti-CD3 and anti-CD28 or IgM for 16 hours and mRNA expression levels of Batf 
were measured to confirm knockdown of Batf (A) and at protein level (B). (C) CD4 and 
CD19 cells from WT or K2/3 mice were measured for IL-2 and proliferation from 
transfected cells with control or Batf siRNA after anti-CD3 and anti-CD28 or IgM for 48 
hours. (D) EMSA was performed on the above transfected cells with the AP-1 DNA probe. 
The data is representative of three experiments [A, B and C] or two experiments [D] (the 
data has been taken from Li et al., 2012, in which I am one of the co-authors). 
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Chapter 4: General Discussion  
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4.1 A deficiency in EGR-2 and EGR-3 results in systemic autoimmune disease 
 
 The causes of autoimmune disease are still unclear and a lot of research is being 
done to elucidate the cause and possible treatment strategies. Autoimmune mouse 
models are extensively used to study autoimmune disease. There are three main types of 
animal models used to study autoimmune disease, firstly the spontaneous model, 
secondly, the inducible model and lastly genetically engineered mice (Morel., 2004). The 
spontaneous model is difficult to manipulate towards human clinical disease. However, 
non-obese diabetic (NOD) mouse do develop type 1 diabetes spontaneously (Morel., 
2004). The lupus mouse model is NZB plus NZW (Farine., 1997). The inducible method is 
more preferred as autoantigens are administered to the mouse and then stimulated to 
induce autoimmune disease. The well-established inducible models include EAE for MS 
and collagen-induced arthritis (CIA) for rheumatoid arthritis (Farine., 1997; Morel., 2004). 
Another arthritis mouse model is type II collagen-induced arthritis (Farine., 1997). The 
mouse model for Hashimoto’s thyroiditis is experimental autoimmune thyroiditis (Farine., 
1997). Lastly, the genetically engineered mice are those that have knockout or over-
expression of a particular gene of interest and typically being used for SLE (Morel., 2004). 
Therefore it will be of interest to unravel more genes and models to study the 
mechanisms of autoimmune disease. 
  Previously our group have shown that older EGR-2ckO mice develop lupus-like 
autoimmune disease and  secrete pro-inflammatory cytokines with high levels of IFN-γ 
and IL-17 at 15 months of age (Zhu et al., 2008), whilst EGR-3KO mice did not develop 
autoimmune disease symptoms (Li et al., 2012). Our group are the first to develop an 
EGR-2 and EGR-3 deficient mouse model which showed an earlier onset of autoimmune 
 104 
 
disease at 2 months compared to single EGR-2cKO. EGR-2 and EGR-3 deficient mice 
displayed systemic autoimmune disease with a multiorgan immunopathology and 
excessive production of autoantibodies in the kidney indicating the possible dose effect 
of EGR-2 and EGR-3 on other functionally related transcription factors. Previously 
polymorphisms of EGR-2 show increased susceptibility for the development of systemic 
lupus disease (Myouzen et al., 2010). Introducing single nucleotide polymorphisms in 
EGR-2 caused an increased susceptibility to develop SLE shown by a high expression of 
those genes prone for the disease (Myouzen et al., 2010). Similarly, inducing SLE 
associated autoimmune disease in mice, displayed defective expression of EGR-2 and 
EGR-3 in auto reactive T cells (Sela et al., 2008). The defective expression of EGR-2 shown 
by this group (Sela et al., 2008) is also consistent with what we observed in the 
expression of EGR-2 in MS patients, where expression levels of EGR-2 were reduced 
(Miao et al., 2013) indicating the importance of this gene in regulating autoimmune 
disease.  
 It has been previously reported that EGR-2 is important for T and B cell 
development, and forced expression of EGR-2 renders low numbers of DP cells in thymus 
and immature B cells in the bone marrow, however percentages of mature T and B cells 
were increased (Li et al., 2011).  In our model EGR-2 and EGR-3 deficient mice showed no 
developmental defects (Li et al., 2012).  
 To further confirm the role of EGR-2 in controlling autoimmune disease we used 
EAE which is the mouse model for MS. The data showed that EGR-2cKO mice developed 
more severe symptoms of the disease from clinical scoring compared with WT. There was 
an excessive accumulation of mononuclear cells in the spinal cord. The CD4 T cells from 
these mice displayed increased pro-inflammatory cytokines IL-17, TNF-α, IL-4 and IFN-γ 
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associated with EAE disease (Bar O’ et al., 1999; Stanislaus et al., 2005). In conclusion 
EGR-2 and EGR-3 intrinsically regulate and protect lymphocytes against the development 
of autoimmune disease.  
 
4.2 Mechanism for the development of autoimmune disease in EGR-2 and EGR-3 
deficient mice 
4.2.1 How chronic inflammation plays the role for autoimmune disease development 
  
 EGR-2 and EGR-3 deficient mice display lethal autoimmune disease and excessive 
production of pro-inflammatory cytokines. Despite this, antigen receptor stimulation of T 
and B cells from EGR-2 and EGR-3 deficient mice displayed defective proliferation and IL-2 
production. There was an excessive production of IFN-γ, GM-CSF, IL-17A and IL-17F in the 
EGR-2 and EGR-3 deficient mice. These cytokines have been shown to be increased in 
autoimmune disease (Langrish et al., 2005; Harris et al., 2007). GM-CSF has been further 
shown to be present in synovial joints from autoimmune disease patients (Hamilton., 
2002).  
 Previously another group have shown high expression levels of IL-17 and IFN-γ in 
EGR-2cKO mice similar to what we have shown (Iwasaki et al., 2013), which confirms 
EGR-2’s important role in cell intrinsic regulation of autoimmune disease.  
 Pro-inflammatory cytokines have been linked to causing inflammation at the site 
of tissue damage. Cytokines including TGF-β, IFN-γ, IL-8 and IL-6 help recruit and activate 
inflammatory type cells like macrophages and endothelial cells. The accumulation of cells 
and induction of proximal and distal cytokines causes swelling and redness surrounding 
the local site, to induce an inflammatory cytokine cascade, which further cause’s tissue 
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damage and eventually leads to organ dysfunction (Blackwell and Christman., 1996; 
Gogos et al.,2000; Sultani et al., 2012).  This further suggests that the increased 
expression of pro-inflammatory cytokines is causative of the inflammatory 
immunopathology observed in EGR-2 and EGR-3 deficient mice. 
 EGR-2 has been shown to induce Treg (iTreg) that express lymphocyte activation 
gene-3(LAG-3) (Okamura et al., 2012). FoxP3 deficient mice exhibited splenomegaly and 
multi-organ autoimmune disease, where FoxP3 is expressed in  naturally occurring Tregs 
(nTreg) and has been associated with the maintenance of tolerance and protecting 
against autoimmune disease (Fontenot et al., 2003). EGR-2 has also been indicated to be 
critical for the regulation of IL-10 producing CD4+ Treg cells. EGR-2 transduced cells 
produce an immunosuppressive function in-vivo suggesting that EGR-2 plays a cell 
extrinsic mechanism in IL-10 producing CD4+ Treg cells however in our EGR-2 and EGR-3 
deficient mice there were no difference for Treg cells compared with WT (Li et al., 2012).  
 In fact the immunopathology observed in K2/3 mice is not due to excessive 
proliferation; it is due to uncontrolled production of pro-inflammatory cytokines. EGR-2 
and EGR-3 directly regulate SOCS1 and SOCS3 expression (Li et al., 2012). STAT1 and 
STAT3 are regulated by their suppressor transcription factors SOCS1 and SOCS3 which are 
important for Th1 and Th17 differentiation (Anderson et al., 2006). We found 
hyperactivation of STAT1 and STAT3 in EGR-2 and EGR-3 deficient B and T cells after 
mitogenic stimulation (Li et al., 2012). STAT-3 deficient mice did not develop severe EAE 
disease compared with WT (Harris et al., 2007). SOCS1 deficient mice contained activated 
T cells and responded to cytokines without antigen receptor stimulation to produce IFN-γ, 
they developed multiorgan inflammatory pathology (Marine et al., 1999; Croker et al., 
2004) very similar to what we found in EGR-2 and EGR-3 deficient mice. EGR-2 and EGR-3 
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deficient lymphocytes showed low expression of SOCS1 and SOCS3 and high STAT1 and 
STAT3 expression and discovered that the promoters of SOCS1 and SOCS3 contain EGR-2 
binding sites (Li et al., 2012). Another group have reported that reduced IL-11 cytokine 
expression leads to hyperactive STAT1 and STAT3 expression resulting in inflammation 
and gastric tumorgenesis (Ernst et al., 2008). We show that an immunopathology exists 
once you have hyperactivation of STAT1 and STAT3 in EGR-2 and EGR-3 deficient mice (Li 
et al., 2012).  
 The link between chronic inflammation and autoimmune disease shows that 
elevated levels of inflammatory cytokines are observed in autoimmune diseases (Langrish 
et al., 2005; Harris et al., 2007). Studying the rheumatoid arthritis model, chronic 
inflammation plays an important role in the disease and arthrosclerosis in coronary heart 
disease (Abou-Raya et al., 2007). They show that inflammation and dysregulation in T and 
B cells causes autoimmune disease and tissue destruction (Abou-Raya et al., 2007). 
Importantly IL-6, pro-inflammatory cytokine has been implicated in several autoimmune 
diseases like rheumatoid arthritis and chronic inflammatory disorders to show the link 
between inflammation and autoimmune disease (Ishihara and Hirano., 2002).  
 In conclusion, EGR-2 and EGR-3 play an intrinsic role in suppressing inflammatory 
mediated immunopathology in autoimmune disease.   
 
4.2.2 Th17 mediated inflammatory autoimmune disease  
 
 Although EGR-2 and EGR-3 have been shown to mediate the STAT1 and STAT3 
inflammatory pathway, STAT3 is also important for Th17 differentiation and pro-
inflammatory cytokines (Harris et al., 2007). IL-17 is a pro-inflammatory cytokine that has 
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been shown to be important for inducing inflammation. IL-17 deficient mice show 
reduced inflammatory responses in the CIA mouse model for rheumatoid arthritis (Nakae 
et al., 2003) and inducing autoimmune disease in EAE (Langrish et al., 2005). It has been 
previously shown that STAT3 is vital for Th17 mediated autoimmune disease, as 
suppression of STAT-3 can decrease Th17 mediated differentiation and drive a Th1 
response. MS patients showed marked increases in mRNA expression levels of IL-17 in 
mononuclear cells and cerebrospinal fluid showing the importance of IL-17 in 
inflammatory induced autoimmune disease (Matusevicius et al., 1999). Loss of SOCS3 in T 
cells resulted in increased Th17 differentiation and IL-10 production (Taleb et al., 2009). 
Previously, IL-23 a cytokine in CD4 T cells can induce differentiation into Th17 cells that 
produce IL-17, IL-17A, TNF, and IL-6 production (Langrish et al., 2005). EGR-2cKO mice 
displayed increased levels of the pro-inflammatory cytokines IFN-γ, IL-17A, IL-17F, IL-6 
and IL-21, signature cytokines produced in Th17 CD4 T cells suggesting that EGR-2 is 
important in regulating the expression of pro-inflammatory cytokines (Miao et al., 2013).  
 Th17 differentiation has also been shown to be driven by Batf, where Schraml et 
al., 2009 group found that Batf is important for IL-17 production and they confirm Batf is 
highly expressed in Th17 cells. The Batf deficient mice showed normal Th1 and Th2 
differentiation with normal or reduced expression of IL-4 for Th2 and IL-12 for Th1 CD4 
producing cells to illustrate that only the Th17 CD4 producing cells are affected (Schraml 
et al., 2009). However, this group show that Batf deficient mice have impaired Th17 
differentiation and were resistant to developing EAE disease. From EGR-2cKO mice we 
observed normal Th1 and Th2 differentiation, whilst Th17 differentiation was significantly 
increased suggesting that only the Th17 lineage was affected (Miao et al., 2013).  
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 CD4 T cell lineage commitment is complex and the ability of Th CD4 T cells to 
switch between subtypes has been reported. The transcription factor T-bet has been 
shown to be important for Th1 differentiation whereas GATA-3 has been shown to be 
important for Th2 differentiation (Zhou et al., 2009). Th1 CD4 T cells produce IFN-γ, IL-12 
and Th2 T cells producing IL-4 signature cytokines (Zhou et al., 2009). Expression of these 
cytokines suppresses IL-17 cytokine expression, thus showing that Th lineages are distinct 
from one another (Zhou et al., 2009). When we explored the role of EGR-2 in the Th CD4 
lineages, we observed that EGR-2 was expressed in the presence of TGF-β and IL-6, 
important Th17 pro-inflammatory cytokines (Zhou et al., 2009; Miao et al., 2013).   
 TGF-β has been associated in systemic autoimmune disease similar to what our 
EGR-2 and EGR-3 deficient mice displayed showing the importance of TGF-β in 
inflammatory induced autoimmune disease (Leveen et al., 2002; Miao et al., 2013). EGR-2 
expression was not induced in the presence of Th1 and Th2 inducers IL-12, IL-4 and IFN-γ 
which further suggests that EGR-2 regulates Th17 differentiation distinctly (Miao et al., 
2013).  
 Although Th17 CD4 T cells have been established to be important for mediating 
inflammatory autoimmune disease pathology, increasingly Tregs have also been shown to 
have a significant importance. The balance of Th17 to Treg is important for the 
maintenance of homeostasis and anergy (Eisenstein and Williams., 2009) to prevent the 
development of autoimmune disease. Th17 is important for inducing the release of pro-
inflammatory cytokines that in turn increase disease pathology in autoimmune disease 
causing tissue and organ damage (Waite and Skokos., 2012). The breakdown in tolerance 
is one contributory factor in autoimmune disease as clinical data has shown that 
autoimmune disease patients have reduced levels of Treg cells (Dejaco et al., 2005). 
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However, in our EGR-2 and EGR-3 deficient mice there was no difference in the Treg 
population or FoxP3 expression (Li et al., 2012).  
 When EGR-2 was reconstituted in the CD4 T cells, IL-17 production was low and 
siRNA knockdown of EGR-2 enhanced the expression IL-17 production (Miao et al., 2013). 
These results confirm Schraml et al., 2009 group showing that EGR-2 interacting with Batf 
is important for suppressing Th17 pro-inflammatory cytokines and therefore 
immunopathology.  
 Previous publications have indicated that other EGR family members are involved 
in inflammatory disease. EGR-1 has been associated with cholestasis in the liver, which is 
an inflammatory disease caused by an increase in bile acids in the liver and blood, where 
EGR-1 deficiency reduced liver inflammation (Allen et al., 2010). A recent group has found 
that EGR-3 induces the expression of the anti-inflammatory cytokine TGF-β1 in human 
and mouse CD4 T cells owing to the role that EGR-3 plays in anergy (Sumitomo et al., 
2013). However we found that EGR-2 not EGR-1 or EGR-3 suppressed Batf mediated 
transactivation of the IL-17 promoter (Miao et al., 2013).  
 A recent study has shown that genetics is not the only risk factor with the 
environmental factors proving to be increasingly critical (Kleinewietfeld et al., 2013). This 
study found that increasing salt concentrations can elicit a more profound Th17 mediated 
CD4 T cell response through activation of the MAPK pathway (Kleinewietfeld et al., 2013).  
More research needs to be done to discover more about the causes of autoimmunity. 
 In conclusion, EGR-2 and EGR-3 are critical for controlling autoimmune disease by 
suppressing pro-inflammatory cytokine production and IL-17 mediated 
immunopathology. 
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4.3 The Role of EGR-2 and EGR-3 in positive regulation of T cell receptor signalling  
  
 Single EGR-2 or EGR-3 knockout mice display normal proliferation after mitogenic 
stimulation. However, a deficiency in both EGR-2 and EGR-3, results in defective cell 
proliferation and IL-2 production. In contrast, EGR-2Tg mice show increased proliferation 
after mitogenic stimulation. This phenomenon of an autoimmune disease phenotype and 
defective T cell proliferation in-vitro is similar to autoimmune disease patient’s data; SLE 
patients show impaired T cell proliferation once stimulated in-vitro (Gattlieb et al., 1979), 
which is consistent with our mouse model. Previously EGR-2 and EGR-3 have been 
considered to be important for anergy (Collins et al., 2008; Seiler et al., 2012) by 
increasing E3 ligases leading to the deterioration of the TCR signalling molecules (Harris et 
al., 2004; Safford et al., 2005; Collins et al., 2008). Safford et al., 2005 group showed that 
EGR-2 and EGR-3 negatively regulate T cell activation by increasing E3 ubiquitin ligase Cbl-
b and evoking immunosuppression in-vitro. IL-2 is an important cytokine for T cell 
activation and IL-2 knockout mice have shown to develop autoimmune disease and 
splenomegaly, owing to reduced Treg and other factors (Wolf et al., 2001; Schimpl et al., 
2002; Geng et al., 2012).  
 We propose that EGR-2 and EGR-3 play uncoupled roles in naïve versus anergic T 
cells. In this case the anergic route is associated with down regulation of MAPK and AP-1 
and the increase in NFAT, with deterioration of TCR signalling by inducing E3 ligases 
(Harris et al., 2004; Safford et al., 2005).  We show that EGR-2 and EGR-3 are important 
for naïve T cell activation in response to mitogenic stimulation where EGR-2 and EGR-3 
deficient lymphocytes have a severe defect in proliferation and IL-2 production in 
response to mitogenic stimulation. The findings represented here are novel.  
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 EGR-2 and EGR-3 have been previously shown to induce apoptosis by directly 
regulating FasL transcription (Mittelstadt and Ashwell., 1999), however we did not 
observe any differences in apoptosis in EGR-2 and EGR-3 deficient mice (Li et al., 2012) 
proving that the defective proliferation is not due to increasing apoptotic activity. 
 In fact we found that the defect in T cell proliferation after mitogenic stimulation 
is due to impairment of AP-1 signalling and not MAPK, NFAT or NF-κB. AP-1 activation is 
vital for initialising T cell activation and IL-2 production (Foletta et al., 1998). We 
demonstrated that EGR-2 and EGR-3 bind with Batf, whose function it is to suppress AP-1 
signalling and is part of the alternative complex seen in EGR-2 and EGR-3 lysates from AP-
1 EMSA analyses. Batf does not contain a trans-activation domain and forced expression 
of Batf in fibroblast cells slows down growth (Echlin et al., 2000; Williams et al., 2001). 
The mouse F9 teratocarcinoma cells (low AP-1 levels) when transfected with the TRE-Lux 
luciferase reporter gene and Batf, showed low AP-1 activation (Echlin et al., 2000). We 
show that EGR-2 and EGR-3 directly interact with Batf and do not regulate Batf 
expression levels (Li et al., 2012). In these instances antigen-mediated responses in naïve 
T cells is strictly regulated. At the early stages of antigen-mediated responses, EGR-2 and 
EGR-3 expression is high and Batf expression is repressed, to allow the expansion of 
activated T and B cells (Li et al., 2012). Once the effector function of T and B cells has 
been carried out, EGR-2 and EGR-3 is rapidly arrested and Batf expression levels are 
restored (Li et al., 2012). This suggests that EGR-2 and EGR-3 are important for the initial 
expansion of naïve T cells after T cell activation and rapidly degraded once expansion is 
completed.  
 Direct interaction between EGR-2 and EGR-3 blocks Batf suppressing AP-1 
signalling as shown by EMSA. Conversely we show that silencing of Batf using siRNA in 
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EGR-2 and EGR-3 deficient CD4 T cells restored AP-1 activation and IL-2 production whilst 
reducing inflammatory cytokine IL-17A.  
 Although we show that EGR-2 and EGR-3 directly interact with Batf in the AP-1 
signalling pathway, we also identified that EGR-2 and EGR-3 deficient nuclear extracts 
contained JunB in the complex, suggesting that EGR-2 and EGR-3 interacting with JunB is 
important for the activation of AP-1. Mice that have a deletion of JunB and c-Jun develop 
psoriasis-like disease and arthritis in the skin where a huge influx of epidermal cytokines 
and inflammation was observed, to indicate that AP-1 proteins are important for 
regulating skin homeostasis and preventing inflammation (Guinea-Viniegra et al., 2009). 
c-Jun has been shown to promote proliferation and differentiation of keratinocytes in the 
epithelium (Schonthaler et al., 2011) and its expression is ubiquitous in dividing cells 
(Johnson et al., 1993). c-Jun knockout primary embryonic fibroblast cells showed reduced 
growth rates in-vitro (Johnson et al., 1993) showing that c-Jun is important in 
proliferation during embryonic development. Also c-Jun knockout fibroblast cells from 
mice showed a severe defect in cell proliferation due to an increase in the tumor 
suppressor gene p53 (Schreiber et al., 1998). The role of c-Jun and JunB has not been 
investigated in our EGR-2 and EGR-3 deficient mouse model.  
  In conclusion we show the essential role of EGR-2 and EGR-3 in positively 
inducing T cell receptor activation after mitogenic stimulation. 
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4.4 Future Considerations/Work 
 
 The work presented in this thesis show EGR-2 is prerequisite for preventing 
autoimmune disease and EGR-2cKO mice are more susceptible to inducing autoimmune 
disease in the EAE model. Future work would be to explore the role of EGR-2 in other 
autoimmune disease mouse models, for example zymosan induced arthritis (Asquith et al., 
2009) as the role of EGR-2 in autoimmune disease is unclear. This could have an impact on 
the use of EGR-2 as a therapeutic agent for controlling autoimmune disease in future 
research.  
 Another important area for future work is the role of EGR-2 and EGR-3 in TCR 
signalling. Overall our results support that EGR-2 and EGR-3 are important for positive 
regulation of T cell activation in response to antigenic stimulation through AP-1 signalling. 
TCR signalling is complex (Morris and Allen., 2012) and we only explored the role of EGR-2 
and EGR-3 in MAPK pathway, it would be interesting to examine their role in the other 
signalling components.  
 Another area for future research would be to explore the role of AP-1 and 
inflammation in our model. AP-1 proteins are also associated with inflammation and a 
report has shown that asthmatic patients show over expression of AP-1 (Jaques et al., 2010). 
Similarly AP-1 over expression has been shown to increase ICAM-1 in human vascular 
endothelial cells (Wang et al., 1999). Jun proteins are important in regulating skin 
inflammation and have been associated in the induction of skin inflammatory diseases 
where a loss of JunB causes SLE disease and the loss of both c-Jun and JunB results in severe 
psoriasis (Sconthaler et al., 2011). This could provide a possible link between the 
autoimmune disease and TCR signalling defect in our EGR-2 and EGR-3 deficient mice. As 
 115 
 
EGR-2 and EGR-3 control both these aspects, we would also want to explore how they 
regulate other transcription factors by using microarray and ChIP sequencing.  
 
4.5 Conclusion  
  
 The work presented in this thesis, illustrate the importance of EGR-2 and EGR-3 
intrinsically controlling the development of chronic inflammatory autoimmune disease. 
Therefore the EGR-2 and EGR-3 deficient mouse model could be potentially used as a 
new model for studying of autoimmune diseases.  
 More importantly we identified a novel finding to support the role of EGR-2 and 
EGR-3 in the positive regulation of antigen receptor activation. This therefore shows the 
profound effect of these transcription factors in the regulation of the immune system. As 
EGR-2 and EGR-3 play an uncoupled role to suppress the induction of inflammatory 
cytokines and development of autoimmune disease, whilst being essential in positive 
induction of T cell activation after mitogenic stimulation. In conclusion the work 
presented in this thesis supports the essential role of EGR-2 and EGR-3 for desirable 
immune response whilst restricting immunopathology.  
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